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Introductory remark 
 
The main part of this work refers to the investigation of the role of inhibitor of apoptosis 
proteins (IAPs) in inflammatory processes of endothelial cells and the effects of an IAP 
antagonist in inflammation. The second part corresponds to the project I worked on 
before that and consists of the published manuscript dealing with the influence of ANP 
on endothelial hyperpermeability. 
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1.1 Background and aim of the study 
XIAP, cIAP1 and cIAP2 are the best characterized mammalian members of the 
inhibitor of apoptosis protein (IAP) family, whose common feature is the appearance of 
variable numbers of baculoviral IAP repeat (BIR) domains. The IAPs, in particular 
XIAP, are implicated in the regulation of apoptosis by interaction with caspases via 
their BIR domains.1, 2 Due to the fact that IAPs often are over-expressed in human 
malignancies,3, 4 they became attractive targets for the development of anti-cancer 
therapeutics based on the structure of the endogenous IAP antagonist Smac.5 The 
peptidic Smac mimetic A-410099.1 (ABT), which we used as a tool for this work, is a 
high affinity, proteolytic stable, small molecule inhibitor modelled to bind to the BIR3 
domain of XIAP with an affinity in a nanomolar Kd range and has been employed for 
anti-cancer strategies.6  
Besides their anti-apoptotic function, IAPs interact with a variety of signaling molecules 
and pathways: The BIR1 domain of XIAP participates in the activation of the MAP3-
kinase TAK1,7 whereas the BIR1 domain of cIAP1 and cIAP2 interacts with the TNF-
receptor associated proteins TRAF1 and TRAF2.8, 9 Additionally to the BIR motifs, 
XIAP, cIAP1 and cIAP2 contain a RING (really interesting new gene) domain with E3- 
ubiquitin protein ligase activity that promotes the transfer of ubiquitin chains to target 
proteins.10 The ubiquitination of proteins can on the one hand promote proteasomal 
degradation or on the other hand contribute to signaling processes. By providing 
ubiquitin platforms, cIAP1 and cIAP2 are important players in the TNF receptor 1 
(TNFR1) signaling. They contribute to the recruitment of TNFR1-associated signaling 
complexes like TAK/TAB (activation of MAPK and NFκB signaling) or IKK/NEMO 
(activation of NFκB signaling).11, 12 
The TNF receptor-associated signaling is a key factor in the induction of inflammatory 
processes. Acute and chronic inflammation is implicated in a number of severe 
diseases like atherosclerosis, arthritis or sepsis. The endothelium, which regulates the 
recruitment of circulating leukocytes and promotes their transmigration from blood to 
the tissue, is a crucial player in inflammation.13 Despite the involvement of cIAP1 and 
cIAP2 in TNFR signaling, there is as yet nothing known about their role in inflammatory 
processes.  
These facts led us to the hypothesis that IAP antagonists function not only as inducers 
of apoptosis but might also have an anti-inflammatory potential and that the IAPs are 
involved in the regulation of inflammatory events. 
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The aims of the study were: 
1. to elucidate if IAP antagonists have an anti-inflammatory potential and 
2. to unravel the role of IAPs in inflammatory processes in endothelial cells. 
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1.2 Inhibitor of Apoptosis Proteins 
1.2.1 Apoptosis 
Apoptosis is a process of programmed cell death which is of physiological importance 
for tissue homeostasis and control of proliferation. In many human disorders apoptosis 
is dysregulated as demonstrated by the excessive cell death in neurodegenerative 
disorders or the insufficient apoptosis in cancer.14 The main actors in apoptosis are 
caspases, a family of proteases, which occur in the cell as inactive zymogens 
(procaspases). The activity of the initiator caspases (caspases 8 and caspases 9) is 
induced upon proapoptotic stimuli and they activate the downstream effector caspases 
(caspases 3 and 7) by proteolytic cleavage.15 The extrinsic pathway triggers apoptosis 
upon binding of proapoptotic ligands to cell surface receptors from the tumor necrosis 
factor receptor (TNFR) family. This results in a recruitment of adaptor proteins 
(TRADD, FADD, Fas) which form the death inducing signaling complex (DISC) and 
activate the procaspase-8.16 Apoptosis goes along with a release of proapoptotic 
factors like cytochrome c (cyt c), or the second mitochondria-derived activator of 
caspases (Smac) from the mitochondrium. There exist several specific cellular 
inhibitors that prevent inappropriate induction of cell death like the inhibitor of apoptosis 
proteins (Figure 1). 
 
 
Figure 1 Apoptotic pathways. The extrinsic pathway triggers apoptosis upon binding of a 
ligand to a receptor from the TNFR family resulting in an activation of caspase-8. Caspase-8 on 
the one hand directly activates the caspases-3 and -7. On the other hand caspase-8 can 
amplify the apoptotic signal via inducing the release of proapoptotic substances (Smac, 
cytochrome c) from the mitochondrium, like the intrinsic activation of apoptosis does, and 
thereby mobilizes the effector caspases-3 and -7. The inhibitor of apoptosis proteins block the 
activation of caspase-3, -7 and -9. 
Smac
effector 
casp-3/-7
casp-9
casp-9 cyt c
apoptosis
cytosol
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1.2.2 The IAP family 
The inhibitor of apoptosis proteins (IAPs) have been identified in many different 
organisms like in yeast, nematodes, flies and higher vertebrates. The iap gene was 
discovered 17 years ago by Miller and colleagues as a gene that inhibits apoptosis in 
virally-infected Spodoptera frugiperda cells.17 The name of the IAPs derives from their 
ability to suppress apoptosis that is triggered by a variety of stimuli.18-20 New insights 
from deletion experiments in mice and Drosophila melanogaster disclose that the IAPs 
also are involved in many other cellular events including signal transduction, 
proliferation and differentiation processes.21 There are at least 8 mammalian members 
of the IAP family: NAIP, ILP2, BRUCE, survivin, livin, X-linked IAP (XIAP), cellular IAP1 
(cIAP1) and cellular IAP2 (cIAP2). XIAP, cIAP1 and cIAP2 are the best-characterized 
members22-24. In mammalian cells IAPs are not inevitable for inhibition of apoptosis but 
regulate the apoptotic response under stress conditions.25 The knockout of XIAP in 
mice does not induce spontaneous apoptosis26 but XIAP exhibits protective effects in 
the survival of post-mitotic neurons27 and cardiomyocytes28.  
 
1.2.3 Structural elements of IAPs 
 
Figure 2 Domain organization of IAPs. (BIR: baculoviral IAP repeat, UBA: ubiquitin-
associated, CARD: caspase recruitment domain, RING: really interesting new gene) 
 
1.2.3.1 The structure and functions of the BIR domains 
The common feature of all IAPs is the occurrence of one to three copies of baculoviral 
IAP repeat (BIR) domains.29 The BIR domains comprise 70 to 80 amino acids and 
contain a conserved C2HC-type zinc finger motif.29, 30 XIAP, cIAP1 and cIAP2 consist 
of three N-terminal BIR domains. Most of the BIR domains contain a surface groove 
that is called IBM-interacting exosite and interacts with N-terminal IAP binding motifs 
BIR1 BIR2 BIR3
linker
RINGUBA
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(IBMs). IBMs occur for example in Smac, the cellular IAP antagonist, and in the 
caspases-3, -7, and -9.31 
Generally, there are specific sequence differences in the BIR domains that result in 
distinct binding properties. Therefore, IAPs containing different BIR domains are able to 
interact with multiple proteins. BIR domains also show association properties. The 
BIR1 domain of XIAP for example forms homodimers.7  
XIAP, cIAP1 and cIAP2 regulate the activity of both, initiator and effector caspases. 
The BIR domains of cIAP1 and cIAP2 efficiently bind to caspases-3, -7, and -9. 
However they most likely do not inhibit them via an interaction between their BIR 
domains and the caspases because they do not possess the precise structural 
elements required for the inhibition of those enzymes.32 Instead, cIAP1 and cIAP2 are 
believed to regulate cell survival by influencing TNFR signaling and caspase-8 
signaling.11  
Most likely, XIAP is the only direct inhibitor of the caspases-3, -7, and -9.32, 33 XIAP 
interacts with caspase-3 via the linker region preceding the BIR2 domain.34 The 
interaction with caspase-7 is mediated by the linker region and the BIR2 domain.35 The 
BIR3 domain interferes with caspase-9.2 
Besides their direct binding to caspases, the IAPs have been shown to interact with a 
number of adaptor proteins and therefore are involved in the regulation of different 
signaling pathways like heavy metal metabolism, cell division, morphogenesis, 
mitogen-activated protein kinase (MAPK) pathways and nuclear factor κB (NFκB) 
activation. In contrast to BIR2 and BIR3, the BIR1-domain of XIAP, cIAP1 and cIAP2 
does not bind caspases but functions in several signaling pathways via an 
oligomerization of binding partners.36 The interaction of the XIAP BIR-1 domain with the 
TGFβ-activated kinase 1 (TAK1) binding protein 1 (TAB1) for example can activate the 
MAP kinase kinase kinase (MAP3K) TAK17 and therefore NFκB signaling. The BIR1 
domains of cIAP1 and cIAP2 similarly interact with TRAF1 and TRAF2,8, 37-39 adapter 
proteins that are associated with TNFR signaling complexes.  
 
Despite structural similarity, the BIR domains are multifaceted protein-protein-
interaction domains that can bind numerous proteins that are involved in diverse 
apoptotic and signaling processes.31 
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1.2.3.2 The UBA and the CARD domains 
The last BIR domains of IAPs (like cIAP1, cIAP2 and XIAP) are followed by a domain 
that is homologous to ubiquitin-associated (UBA) domains. It enables IAPs to bind 
ubiquitin residues.31  
Some members of the IAP family, like cIAP1 and cIAP2, are characterized by the 
occurrence of a homotypic dimerization domain, the caspase recruitment domain 
(CARD).40 This domain is recognized in a increasing number of proteins that participate 
in apoptotic or inflammatory signaling complexes.41 
 
1.2.3.3 The RING domain 
The C-terminal really interesting new gene (RING) zinc-finger domain possesses E3 
ubiquitin ligase activity which mediates IAP autoubiquitination as well as the 
ubiquitination of other proteins like caspases-3, -7, and -9,42, 43 TRAF1, TRAF2 and 
RIP,37, 44 Smac,43 and NEMO/IKKγ.10, 45, 46 The conjugation of ubiquitin requires an 
ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2), and an 
ubiquitin protein ligase (E3).47 E3 ligases facilitate the generation of an isopeptide bond 
between the C-terminus of ubiquitin and the amino group of a reactive side chain of the 
substrate, mostly a lysine residue (K).48 The seven K residues of ubiquitin can accept 
further attachment of ubiquitin resulting in a formation of polyubiquitin chains. The 
linkage of the ubiquitin chains determines the fate of the modified protein. K48-linked 
polyubiquitin chains render the modified protein to degradation by the 26S 
proteasome.44 In contrast, K63-linked polyubiquitin chains as well as 
monoubiquitination are involved in a variety of nondegradative signaling processes. 
They often serve as a kind of scaffold for the association of other proteins in order to 
build signaling platforms34-36 or alter the activation of the modified protein 
(NEMO/IKKγ).46, 49  
The ubiquitination processes exerted by their RING domains (K48 and K63) allow 
cIAP1 and cIAP2 to contribute to several signaling pathways, for instance the TNFR 
signaling. 
1.2.3.4 IAPs in TNFR signaling 
Many biological responses are achieved by TNFα signaling. The cytokine can be 
involved in the induction of other pro-inflammatory cytokines, cell proliferation, 
differentiation or cell death.50 The pathogenesis of many human diseases like cancer, 
1  INTRODUCTION 17 
  
 
sepsis, diabetes and autoimmune diseases involves inadequate TNFα signaling.51 
Notably, most cancer cells pass on to autocrine TNFα signaling.52, 53 TNFα binds to two 
cell surface receptors: TNFR1 and TNFR2. The TNFR1 is the best-characterized 
receptor for TNFα and mediates most of the TNFα-induced effects whereby 
ubiquitination processes play an important role.54 TNFR1 activates caspase-8, the 
transcription factor NFκB and MAPKs like p38 and JNK.36, 55  
The association of cIAP1 and cIAP2 with the RING domain-containing proteins TRAF1 
and TRAF2 assigns cIAP1/2 to be components of TNFR1-associated signaling 
complex.23, 56-59 Binding of TNFα induces a trimerization of TNFR1 and stimulates the 
formation of the TNFR-associated signaling complex I. This involves the death domain-
mediated binding of the adapter protein TNF receptor-associated protein with death 
domain (TRADD) to the cytoplasmic tail of TNFR1.60 TRADD immediately recruits 
TRAF2, the receptor-interacting protein 1 (RIP1) and cIAP1 and cIAP2.12, 61-64 cIAP1 
ubiquitinates several components of the TNFR-associated complex I, including itself 
and RIP1 (K63-linked ubiquitination), which facilitates the recruitment of the IκB kinase 
(IKK) complex and the TAB/TAK complex. The outcome of this is the activation of 
NFκB and MAPK signaling promoting prosurvival and proinflammatory transcriptional 
response.53, 65  
In cancer cells, cIAP1 and cIAP2 seem to be crucial for the induction of the TNFα-
caused NFκB activation and therefore protect the cells from TNFα-mediated cell 
death.52, 58 Additionally, the presence of cIAP1 and cIAP2 in the TNFR1-associated 
signaling complex is essential for the inhibition of caspase-8.23, 66 The K63-linked 
ubiquitination of RIP1 seems to prevent its release from the TNFR-associated complex 
and therefore the recruitment and activation of FADD and caspase-8.57, 67, 68  
Thus, cIAP1 and cIAP2 are crucial players in TNFR1 signaling (Figure 3) and important 
regulators of apoptosis although they are not able to directly inhibit the activation of 
caspases via their BIR2 and BIR3 domains. 
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Figure 3 IAPs in TNFR-associated signaling. 
 
1.2.4 IAP antagonists 
In many human malignancies IAPs are often overexpressed going along with a poor 
survival prognosis for the patient (cIAP1: multipla myeloma, various carcinomas; 
cIAP2: MALT lymphoma, multiple myeloma, various carcinoma; XIAP: X-linked 
lymphoproliferative disorder).68 The upregulation of IAPs causes resistance of cancer 
cells to chemotherapy and radiation.69 Therefore, the IAPs are interesting targets for 
the development of new anti-cancer drugs, such as small molecule IAP antagonists. 
These IAP antagonists are designed on the basis of the interaction of Smac, the 
endogenous IAP inhibitor, with XIAP.6 
 
1.2.4.1 Smac 
Smac is encoded by a nuclear gene and is subsequently imported into mitochondria. 
Mature Smac is generated by cleavage of the N-terminus.70, 71 It is released from the 
mitochondrium upon proapoptotic stimuli to inhibit the activity of IAPs and to enable the 
induction of apoptosis. The Ala1-Val2-Pro3-Ile4 (AVPI) residues exposed at the N-
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terminus of mature, dimeric Smac interacts with a surface groove in the BIR2 and BIR3 
but not with the BIR1 domain of XIAP.72 Smac competes with caspase-9 for binding to 
the BIR3 domain of XIAP and therefore gives rise to induction of apoptosis.5, 72, 73 Even 
though Smac does not interact with the BIR1 domain, Smac binding to the BIR2 and 
BIR 3 domains of XIAP, respectively, induces changes affecting the BIR1 interactions 
with its downstream targets. In particular, Smac prevents full-length XIAP BIR1/TAB1 
interactions.7 
Recent studies showed that, besides preventing the XIAP-caspases-9 interaction, 
Smac and synthetic Smac mimetics target cIAP1 and cIAP2 by induction of their 
autoubiquitination followed by their proteasomal degradation.59, 74 In the contrary, Smac 
(and some of the IAP antagonists) does not induce the degradation of XIAP.74, 75 As 
members of the TNFR1-associated signaling complex, cIAP1 and cIAP2 suppress the 
activation of caspase-8. The Smac- or IAP antagonist-induced loss of cIAP1 and cIAP2 
alters TNFR signaling regarding ubiquitination processes and NFκB activation and 
therefore sensitizes cells to TNFα-mediated apoptosis.11, 67 
 
1.2.4.2 Synthetic monovalent Smac mimetics 
Since the therapeutic use of peptides is constraint by proteolytic stability, limited cell 
permeation and poor pharmacokinetics the development of synthetic Smac mimetics 
aims in achieving cell permeable, high affinity and proteolytic stable IAP antagonists. 
Oost et al. 20046 used the pentapetide N-terminus AVPFY of the functional Smac 
homologue HID (head involution deficiency), which is characterized by a better binding 
affinity for the XIAP BIR3 domain than AVPI, as a starting point for the generation of 
four peptide libraries. In these peptide libraries each of the first four residues had been 
varied, while the other four were left unchanged. By analyzing the structure-activity 
relationships (SAR), they gained a series of proteolytically stable, capped tripeptides 
comprised of unnatural amino acids that are shown to bind to the XIAP BIR3 domain 
with low nanomolar affinity. One of these synthetic peptides, the compound 11 (also 
called: A-410099.1 or in the following: ABT) is depicted in Figure 4 and was used for 
this work. It exhibits cytotoxic effects in cancer cell lines and was successfully applied 
in a MDA-MB-231 breast cancer mouse xenograft model. It binds to the BIR3 domain 
of XIAP with a Kd of 16 nM. 
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Figure 4 Synthetic IAP antagonist: A-10099.1 (ABT, Compound 11; Oost et al. 2004) 
 
Recently, IAP antagonists have come into the focus of attention of many research 
groups. On the one hand, IAP antagonists sensitize cancer cells to TNFα-induced 
apoptosis and, therefore, they render the IAPs to be an outstanding therapeutical 
target.76 The Smac mimetics developed by the companies Aegara (Human Genome 
Sciences, Rockvill, MD, USA) and Genentech (San Francisco, CA, USA/Abbott) have 
already reached clinical trials phase I.68, 69 On the other hand, IAP antagonists are 
designed and used by several other research groups to uncover the exact role of IAPs 
and TNFR signaling in apoptotic processes.68, 77, 78  
Despite the knowledge about the participation of IAPs in NFκB and TNFR signaling, 
which are not only involved in apoptosis but also critical mediators of inflammation, until 
now there is nothing known about the role of IAPs in inflammatory processes of 
endothelial cells. 
 
1.3 Endothelium 
The endothelium is the innermost cell monolayer of blood vessels separating the lumen 
from the tissue. It is not just like a wall paper lining the vessels but fulfills, not at least 
due to its strategic position, important functions regarding vessel tone homeostasis, the 
supply of the tissue with nutrients and gasses, tissue fluid homeostasis, hemostasis, 
and angiogenesis, and host defense.79-81 To implement the tasks of macromolecular 
transport, tissue fluid homeostasis and regulation of leukocyte transmigration the 
endothelium shows the properties of a semi-permeable barrier.80 
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1.3.1 Endothelial permeability 
Under physiological conditions, the endothelial cell barrier tightly regulates the 
permeation of liquids and solutes. Macromolecules like plasma proteins are transported 
on the vesicle-mediated transcellular pathway. The endothelium allows the passive 
paracellular diffusion of small macromolecules but restricts the free passage of bigger 
macromolecules through the minute gaps that arise from the interendothelial junctions 
(IEJ).82 The endothelial barrier function is maintained by a balance between adhesive 
forces represented by the IEJs, which are connected to the actin cytoskeleton and the 
contractile forces, that result from the interaction of myosin with the actin 
cytoskeleton.80 The interendothelial junctions consist of tight junctions and mainly of 
adherens junctions (AJ). These are composed of vascular endothelial cadherin (VE-
cadherin).80 VE-cadherin interacts homotypically and this interaction is Ca2+-dependent. 
Changes in the phosphorylation state of VE-cadherin, for example evoked by protein 
kinase C (PKC), regulate the AJ stability by inducing the internalization of VE-
cadherin.83 The juxtamembrane domain of VE-cadherin is linked to p120 catenin 
whereas the C-terminal domain binds α- and β-catenin, which link VE-cadherin to the 
actin cytoskeleton.84 p120 provides a scaffold function and controls the interaction of 
VE-cadherin with important regulators of vascular endothelial permeability like Rho-
GTPases or phosphatases. The interaction of VE-cadherin with the cortical actin 
cytoskeleton stabilizes the AJ while the reorganization of actin into stress fibers 
mediates cellular contraction and disrupts the AJ.80 These contractile forces are 
generated by the interaction of the stress fiber components myosin II and actin induced 
by a phosphorylation of the regulatory myosin light chain 2 (MLC2). MLC2 is 
phosphorylated by the Ca2+/calmodulin-dependent MLC kinase (MLCK). The 
phosphorylation of MLC2 can also be influenced by the downstream effector of the 
small GTPase RhoA, Rho Kinase (ROCK), that inhibits the MLC2 phosphatase (MYPT) 
activity.85 While RhoA activity and intracellular increase of Ca2+ show barrier disrupting 
properties, the activity of the small Rho GTPase Rac1 and an increase of intracellular 
cAMP levels result in a barrier protection.80 
Several inflammatory mediators like thrombin, histamine, or VEGF induce endothelial 
barrier dysfunction, which causes an uncontrolled efflux of fluid and macromolecules to 
the tissue causing edema formation.80 
Besides its involvement in blood clotting, the procoagulant serine protease thrombin 
induces endothelial hyperpermeability and is a frequently used stimulus for the 
investigation of vascular endothelial permeability.86 Thrombin mediates its barrier 
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disrupting effects by cleavage of the protease-activated receptor (PAR1) receptor 
which results in an increase of intracellular Ca2+ levels. The rising of Ca2+ causes the 
activation of MLCK and PKC. In turn, PKC induces phosphorylation of VE-cadherin as 
well as the activation of RhoA (Figure 5). Therefore, thrombin evokes a loss of barrier 
integrity by internalization of VE-cadherin and induction of cell contraction.80 
The damage of endothelial barrier function is a hallmark of inflammatory diseases like 
sepsis or respiratory distress syndrome. It leads to organ dysfunction by edema 
formation or promotes disease progression by exposure of the underlying tissue to pro-
inflammatory and coagulation mediators.87-89  
Thus, to effectively treat inflammatory diseases it would be of great advantage if an 
anti-inflammatory drug shows barrier protective properties as well. 
 
 
Figure 5 Structural organization of endothelial barrier function and barrier disruptive 
processes induced by thrombin. 
 
1.3.2 Endothelium and inflammation 
Inflammation is important for the host defense or for repairing tissue damage but it 
shows detrimental properties in chronic diseases like atherosclerosis, rheumatoid 
arthritis or asthma. The endothelium is a crucial player in inflammatory diseases 
because it is involved in the recruitment and transmigration of leukocytes to the site of 
inflammation in the tissue. After clearance of an infection, normally the leucocytes 
disappear and the endothelium readopts its quiescent state.90 
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1.3.2.1 Leukocyte recruitment 
The immune response to pathogens depends on the production of chemokines and 
cytokines that are released upon recognition of pathogens. The inflammatory response 
results in the recruitment of activated phagocytes. It is mediated by adhesion 
molecules that are induced on the cell surface of cytokine-activated endothelium.91 The 
first leukocytes that are recruited to the endothelium are the neutrophils followed by the 
monocytes that differentiate to macrophages in the tissue.91 The leukocyte recruitment 
and transmigration can be divided into 4 steps in the innate as well as in the adaptive 
immune response: 1. Selectin-mediated rolling adhesion, 2. Activation by chemokines 
3. Integrin-mediated firm adhesion/arrest and 4. Transmigration (Figure 6).92 At 
inflammatory sites, blood flow is slowed down due to vasodilation, which enables the 
leukocytes to leave the bloodstream and get in contact with the endothelium. The initial 
rolling of the leukocytes on the endothelium is due to transient weak interactions and 
involves L-selectin, which is expressed on leukocytes, and P- and E-selectin expressed 
on endothelial cells.93-95 The process of leukocyte rolling and the following firm 
adhesion involves the leukocyte β1 and β2 integrins very late antigen-4 (VLA-4), 
lymphocyte function-associated antigen-1 (LFA-1/CD11a-CD18) and CD11b-CD18 
(MAC1) which interact with the immunoglobulin family adhesion molecules vascular cell 
adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) 
expressed on endothelial cells. The leukocytes locally secrete cytokines like TNFα, 
which causes the upregulation of adhesion molecule expression on endothelilal cells 
(ICAM-1 and VCAM-1) and elicits the endothelial production of additional, specific 
cytokines (like IL-8). These cytokines rapidly trigger a structural change of the β1 and 
β2 integrins resulting in a firm interaction of VLA-4 with VCAM-1 and of LFA1, or MAC-
1 with ICAM-1.96-100 The final step of leukocyte transmigration is the diapedesis of the 
leukocytes through the vessel wall into the inflamed tissue. ICAM-1 and CD11-CD18 
participate in the crawling of leukocytes into the blood vessel. Inflammatory cytokines 
and the interaction with the leukocytes cause a transient opening of the intercellular 
contacts (adhesion junctions and tight junctions) and facilitate the paracellular 
transmigration.92, 101 The immunoglobulin family proteins ICAM-1, the 
platelet/endothelial cell adhesion molecule-1 (PECAM-1) and the tight junction proteins 
junctional adhesion molecules (JAMs) are responsible for the leukocyte 
transendothelial migration. Thereby, LFA-1 constitutes the binding partner of ICAM-1, 
PECAM-1 interacts homo-typically, and JAMs can associate with integrins.102 Lastly, 
leukocytes have to pervade the perivascular basement membrane. This occurs in 
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regions of low matrix protein deposition and seems to involve proteases like neutrophil 
elastase.103 
 
 
Figure 6 Leukocyte recruitment and transmigration. (LC: leukocyte; EC: endothelial cell) 
 
Thus, endothelial cells actively participate in all steps of leukocyte recruitment in the 
innate and adaptive immune response. Thereby, a tight regulation of this process and 
the integrity of cell junctions is necessary to avoid diseases like arthrosclerosis, 
rheumatoid arthritis, or chronic inflammation.92 
 
1.3.2.2 Signaling involved in inflammatory activation of endothelial cells 
As mentioned in 1.2.3.4 “IAPs in TNFR signaling”, the cytokine TNFα is involved in 
diverse signaling processes and it is a key regulator in apoptosis and inflammatory 
response. TNFα stimulates the inflammatory activation of endothelial cells in terms of 
facilitating leukocyte recruitment, vascular leakage and it promotes thrombosis. It is 
produced by a wide variety of cells.104 TNFR1 initiates the majority of TNFα biological 
activities.52, 105 The activation of TNFR1 induces the association of the intracellular 
death domain of TNFR1 with the death domain of TRADD, which is followed by the 
recruitment of TRAF2, RIP1, cIAP1 and cIAP2 including several ubiquitination 
processes exerted by the cIAPs and TRAF2. As described above, this causes an 
ubiquitin-dependent recruitment of the TAB/TAK and IKK complex and results in an 
activation of NFκB and of MAPK signaling initiating the pro-inflammatory activation of 
the endothelium.106 
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NFκB signaling 
The transcription factor NFκB is a central player in initiation and maintenance of 
inflammation because it regulates the further expression of genes encoding for 
cytokines and endothelial adhesion molecules like E-selectin, VCAM and ICAM-1.107 It 
binds to DNA sequences called κB elements in promoters and enhancers of 
transcrition.108 There are 5 mammalian members of the NFκB family, RelA (p65), RelB, 
cRel, p50/p105 (NFκB1) and p52/p100 (NFκB2) which form homodimeric and 
heterodimeric complexes. In the canonical pathway induced by TNFα (Figure 7), the 
inhibitor of NFκB α (IκBα) retains the NFκB p50/p65 dimer in the cytoplasm. The 
activated IκB Kinase (IKK) complex phosphorylates IκBα resulting in its subsequent 
proteasomal degradation. This is followed by a release of the NFκB dimer which then 
can translocate to the nucleus.109, 110 The IKK complex consisting of the catalytic 
subunits IKKα and IKKβ and the regulatory subunit IKKγ/NEMO is activated upon 
recuitment to the TNFR-associated signaling complex where NEMO is ubiquitinated 
(K63).106 Moreover, the MAP3K TAK1 can activate IKKβ when on the one hand the 
activity of the TAB/TAK complex is induced by hooking on the ubiquitin platform of 
TNFR-associated signaling complex111 or on the other hand, by the direct interaction of 
XIAP with TAB17.  
 
 
Figure 7 NFκB signaling. 
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MAPK signaling 
Like NFκB signaling, the MAPK signaling integrates various stimuli and regulates a 
variety of cellular processes ranging from survival and apoptosis, differentiation and 
proliferation to cellular stress and inflammation.112, 113 Besides NFκB, the TNFα-
induced activation of MAPKs plays an important role in endothelial activation and in 
inflammatory processes.114 The mammalian MAPKs comprise 3 major groups 
consisting of extracellular signal regulated kinase 1/2 (ERK1/2), p38 and c-Jun N-
terminal kinase (JNK). The activity of the MAPKs (ser/thr kinases) is regulated by an 
upstream MAPK phosphorylation cascade. The MAPKs all share a T-X-Y motif where 
they are dually phosphorylated by MAPK kinases (MAPKKs or MEKs). In turn, 
MAPKKs are activated by MAPKK kinases (MAPKKKs or MEKKs), whose activation is 
usually induced by a ligand binding to a receptor, like the TNFR1.112 115 (Figure 8) The 
MAPKKs for p38 are MKK3/6, while JNK is phosphorylated by MKK4/7. The MAPKKs 
of JNK and p38 are activated by the MAPKKK TAK1, ASK1 and MEKK1-4. Theses 
MAPKKK respond to TNFR signaling as shown above for TAK1, which is not only 
implicated in NFκB but also p38 and JNK activation.116 ERK, p38 and JNK are all 
known to be induced by the cytokines TNFα and IL-1.117 Despite ERK is mainly 
implicated in the response to growth factors, in vivo and in vitro data also indicate an 
involvement of ERK in inflammation.115 The activated MAPKs bind and phosphorylate 
their targets in cytoplasm or translocate to the nucleus and induce gene 
transcription.118 p38 and JNK activate the transcription factors c-Jun (TSFs), Elk-1, 
ATF2 and STAT3,115, 119 while ERK1/2 phosphorylates the transcription factor Elk-1.117 
Elk-1 and STAT3 are required for the activation of the c-fos promoter and ATF2 and c-
Jun induce the transcription from the c-Jun promoter. This results in expression of 
members of the Fos and Jun family of transcription factors. Heterodimers of the Fos 
and Jun family constitute the transcription factor AP-1. Since the ICAM-1 promoter 
contains several AP-1 binding sites, the MAPKs ERK, p38 and JNK are involved in the 
regulation of ICAM-1 expression.13, 119  
 
Because of their activities in TNFR signaling and in TAK activation cIAP1, cIAP2 and 
XIAP are involved in the induction of MAPK and NFκB signaling.7, 56, 58 
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Figure 8 MAPK signaling cascade. (TSF: transcription factor) 
 
To sum up, the inhibitor of apoptosis proteins can interact with a variety of proteins and 
therefore participate in several signaling pathways. These pathways are often closely 
interconnected like inflammation and apoptosis. Despite the clear involvement of XIAP, 
cIAP1 and cIAP2 in NFκB and TNFR signaling, which are the basis for apoptotic and 
inflammatory processes, until now the role of the IAPs has been only recognized with a 
view to apoptosis. 
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2.1 Materials 
2.1.1 Biochemicals and inhibitors, dyes and cell culture reagents 
Table 1 Biochemicals, inhibitors, dyes, and cell culture reagents 
Reagent Producer 
Accustain®  formaldehyde Sigma-Aldrich, Taufkirchen, Germany 
Amphotericin B PAA Laboratories, Pasching, Austria 
BC Assay reagent Interdim, Montulocon, France 
Bradford ReagentTM Bio-Rad, Munich, Germany 
Collagen A/G Biochrom AG, Berlin, Germany 
Collagenase A Biochrom AG, Berlin, Germany 
Complete® Roche diagnostics, Penzberg, Germany 
Dianisidinehydrochlorid Sigma-Aldrich, Taufkirchen, Germany 
Dihydrorhodamine-123 (DHR) Invitrogen, Karlsruhe, Germany 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
Endothelial Cell Growth Medium (ECGM) Provitro, Berlin, Germany 
FCS gold PAA Laboratories, Pasching, Austria 
fMLP Sigma-Aldrich, Taufkirchen, Germany 
Formaldehyde, 16% ultrapure Polysciences Europe GmbH, Eppelheim, 
Germany 
M199 Medium PAA Laboratories, Pasching, Austria 
NaF  Merck, Darmstadt, Germany 
Na3VO4  ICN Biomedicals, Aurora, Ohio, USA 
Page RulerTM Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Penicillin PAA Laboratories, Pasching, Austria 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
PermaFluor mounting medium Beckman Coulter, Krefeld, Germany 
PMSF  Sigma Aldrich, Munich, Germany 
Q-VD-OPh R&D Systems, Wiesbaden, Germany 
SB203580 Enzo Life Sciences, Lörrach, Germany 
SP600125 Enzo Life Sciences, Lörrach, Germany 
Streptomycin PAA Laboratories, Pasching, Austria 
Thrombin Sigma Aldrich, Taufkirchen, Germany 
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Reagent Producer 
Tumor necrosis factor α (TNFα) PeproTech GmbH, Hamburg, Germany 
Triton X-100 
 
Merck, Darmstadt, Germany 
Table 2 IAP antagonists 
Compunds Producer 
A-410099.1 (ABT) Abbott Bioresearch Corp. Worcester, MA, 
USA 
Smac066 (monomeric IAP antagonist)120 P. Seneci, Milano, Italy 
Smac085 (dimeric IAP antagonist) P. Seneci, Milano, Italy 
Table 3 Commonly used buffers 
HEPES buffer (pH 7.4)  PBS+ Ca2+/Mg2+ (pH 7.4) 
NaCl 125 mM  NaCl  137 mM
KCl 3 mM  KCl 2.68mM
NaH2PO4 1.25 mM  Na2HPO4  8.10 mM
CaCl2 2.5 mM  KH2PO4  1.47 mM
MgCl2 1.5 mM  MgCl2  0.25 mM
glucose 10 mM  H2O   
HEPES 10 mM    
H2O  PBS (pH 7.4)  
  NaCl  132.2 mM
  Na2HPO4  10.4 mM
  KH2PO4  3.2 mM
  H2O  
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Table 4 Technical equipment 
Name Device Producer 
AB7300 RT-PCR Real-time PCR system Applied Biosystems, 
Foster City, CA, USA 
Axioskop Upright microscope Zeiss, Jena, Germany 
Culture flasks, plates, 
dishes 
Disposable cell culture 
material 
TPP, Trasadigen, 
Switzerland 
Curix 60 Tabletop film processor Agfa, Cologne, Germany 
Cyclone Storage Phosphor Screens Canberra-Packard, 
Schwadorf, Austria 
FACSCalibur Flow cytometer Becton Dickinson, 
Heidelberg, Germany 
ibidi slides  Microscope slide ibidi GmbH, Munich, 
Germany 
LSM 510 Meta 
 
Confocal laser scanning 
microscope 
Zeiss, Jena, Germany 
Mikro 22R Table centrifuge Hettich, Tuttlingen, Germany 
Nanodrop® ND-1000 Spectrophotometer Peqlab, Wilmington, DE, 
USA 
Nucleofector II Electroporation device Lonza GmbH, Cologne, 
Germany 
Odyssey 2.1 Infrared Imaging System  LI-COR Biosciences, 
Lincoln, NE, USA 
Orion II Microplate 
Luminometer 
Luminescence Berthold Detection Systems, 
Pforzheim, Germany 
Polytron PT1200 Ultrax homogenizer Kinematica AG, Lucerne, 
Switzerland 
SpectraFluor PlusTM Microplate multifunction 
reader 
Tecan, Männedorf, Austria 
SunriseTM Microplate absorbance 
reader 
Tecan, Männedorf, Austria 
Vi-Cell™ XR Cell viability analyzer Beckman Coulter, Fullerton, 
CA, USA 
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2.2 Cell culture  
2.2.1 Solutions and reagents 
The following solutions and reagents were used for the isolation as well as for the 
cultivation of endothelial cells. 
Table 5 Solutions and reagents for cell culture 
Growth medium  Stopping medium 
ECGM 500 ml  M 199 500 ml
Supplement 23.5 ml  FCS 50 ml
FCSgold 50 ml   
Antibiotics 3.5 ml   
 
Trypsin/EDTA (T/E)  Collagen A 
Trypsin  0.05%  Collagen A 10%
EDTA  0.20%  PBS  
PBS      
 
Collagen G 
Collagen G 0.001%
PBS 
 
 
For heat inactivation, FCSgold was partially thawed for 30 min at room temperature. 
Subsequently, it was totally thawed at 37°C. Finally, FCS was inactivated at 56°C for 
30 min. FCS was stored at -20°C. 
 
2.2.2 Endothelial cells 
Endothelial cells (ECs) were cultured under constant humidity at 37°C and with 5% 
CO2 in an incubator (Heraeus, Hanau, Germany). Cells were routinely tested for 
contamination with mycoplasm using the PCR detection kit VenorGeM (Minerva 
Biolabs, Berlin, Germany). 
2  MATERIALS AND METHODS 33 
  
 
2.2.2.1 HMEC-1 (Human microvascular endothelial cells) 
The cell line CDC/EU.HMEC-1 was kindly provided by the Centers for Desease Control 
and Prevention (Atlanta, GA, USA). The immortalized HMEC-1 cell line was created by 
transfection of human dermal microvascular endothelial cells with a plasmid coding for 
the transforming SV40 large T-antigen. HMEC-1 were shown to retain endothelial 
morphologic, phenotypic, and functional characteristics.77, 78 HMECs were used for 
macromolecular permeability assays. 
 
2.2.2.2 HUVECs (Human umbilical vein endothelial cells) 
Human umbilical cords were kindly provided by Klinikum München Pasing, Frauenklinik 
Dr. Wilhelm Krüsmann, and Rotkreuzklinikum München. After childbirth, umbilical cords 
were placed in PBS+Ca2+/Mg2+ containing penicillin (100 U/ml) and streptomycin (100 
µg/ml), and stored at 4°C. Cells were freshly isolated every week. The umbilical vein 
was washed with PBS+Ca2+/Mg2+, filled with 0.1 g/l collagenase A, and incubated for 
45 min at 37°C. To isolate endothelial cells, the vein was flushed with stopping medium 
and the eluate was centrifuged (1,000 rpm, 5 min). Afterwards, cells were resolved in 
growth medium and plated in a 25 cm2 flask. After reaching confluence, cells were 
trypsinized and plated in a 75 cm2 flask. Experiments were performed using cells at 
passage 3. HUVECs were used for all assays except for the macromolecular 
permeability assay. 
 
2.2.3 Passaging 
After reaching confluency, cells were either sub-cultured 1:3 in 75 cm2 culture flasks or 
seeded either in multiwell-plates or dishes for experiments. For passaging, medium 
was removed and cells were washed twice with PBS before incubation with 
trypsin/ethylene diamine tetraacetic acid (EDTA) (T/E) for 1-2 min at 37°C. Thereafter, 
cells were gradually detached and the digestion was stopped using stopping medium. 
After centrifugation (1,000 rpm, 5 min, 20°C), the pellet was resuspended in growth 
medium and cells were plated. 
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2.2.4 Freezing and thawing 
For freezing, confluent HMECs from a 75 cm2 flask were trypsinized, centrifuged (1,000 
rpm, 5 min, 20°C) and resuspended in 3 ml ice-cold freezing medium. 1.5 ml aliquots 
were frozen in cryovials. After storage at -80°C for 24 h, aliquots were moved to liquid 
nitrogen for long term storage. 
For thawing, a cryovial was warmed to 37°C and the content was immediately 
dissolved in prewarmed growth medium. In order to remove DMSO, cells were 
centrifuged, resuspended in growth medium and transferred to a 75 cm2 culture flask. 
 
2.2.5 Isolation of human neutrophil granulocytes 
Human neutrophil granulocytes were separated from heparinized peripheral blood of 
healthy volunteers. The blood samples were centrifuged (1,400 rpm, 15 min, without 
additional deceleration) to separate the blood cells from the plasma. The “buffy coat” 
(the layer between the erythrocytes and plasma where the granulocytes are 
sedimented) was collected and CD15 MicroBeads (Mini-Macs, Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany) were added for 30 min at 4°C and for magnetic tagging 
of the neutrophil granulocytes (the main population of CD15+ cells). Using MACS® 
column technology (Miltenyi Biotec, Bergisch Gladbach, Germany), CD15+ cells were 
separated and collected in granulocyte isolation buffer. Cells were counted and kept at 
room temperature in HEPES buffer or granulocyte medium until use (usually within 30 
min). Assays using neutrophils were performed at 37°C.  
Table 6 Buffer and medium for granulocyte isolation 
Granulocyte isolation buffer  Granulocyte medium 
PBS 500 ml M 199 500 ml
BSA 2.5 ml FCS 10 ml
EDTA 2 mM Antibiotics 3.5 ml
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2.3 Preparation of protein samples 
2.3.1 Total cell lysates 
Endothelial cells were treated as indicated, washed once with icecold PBS and 
subsequently lysed in RIPA lysis buffer or in modified RIPA lysis buffer (phospho-
proteins). Immediately, cells were frozen at -80°C. Afterwards, cells were scraped off 
and transferred to Eppendorf tubes (Peske, Aindling-Arnhofen, Germany) before 
centrifugation (14,000 rpm, 10 min, 4°C). Protein concentration was determined in the 
supernatant using the BCA and the Bradford assay, respectively. Afterwards, Laemmli 
sample buffer (3x) or 5x SDS sample buffer was added and samples were heated at 
95°C for 5 min. Samples were kept at -20°C until Western blot analysis. 
Table 7 Buffers for the preparation of total cell lysates 
RIPA buffer   Lysis buffer for phospho-proteins 
Tris/HCl 50 mM  Tris/HCl 50 mM
NaCl 150 mM  NaCl 150 mM
Nonidet NP 40 1%  Nonidet NP 40 1%
Deoxycholic acid 0.25%  Deoxycholic acid 0.25%
SDS 0.10%  SDS 0.10%
H2O  Na3VO4 0.3 mM
Complete® 4.0 mM  NaF 1.0 mM
PMSF 1.0 mM  β-Glycerophosphate 3.0 mM
Na3VO4 1.0 mM  Pyrophosphate 10 mM
NaF 1.0 mM  H2O 
  Complete® 4.0 mM
  PMSF 1.0 mM
  H2O2 600 µM
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Table 8 Sample buffer 
5x SDS-sample buffer   3x Laemmli buffer 
Tris/HCl 3.125 M, pH 6.8  Tris/HCl 187.5 mM
Glycerol 10 ml  SDS 6%
SDS 5%  Glycerol 30%
DTT 2%  Bromphenolblue 0.025%
Pryonin Y 0.025%  H2O 
H2O  β-Mercaptoethanol 12.5%
 
2.3.2 Immunoprecipitation 
For immunoprecipitations Protein A Agarose beads (Sigma-Aldrich, Munich, Germany) 
were incubated with TAB1 antibody (Cell Signaling Technology/NEB, Frankfurt am 
Main, Germany) (2 µg per 50 µl unpacked beads) at 4°C overnight. Cells were scraped 
in non-denaturating lysis buffer and kept on ice for 30 min. Thereafter, the samples 
were centrifuged and protein concentrations were determined in the supernatants. Cell 
lysates were incubated with the Protein A Agarose beads (Sigma-Aldrich, München 
Germany) for 2 h at 4°C. After three washing steps with non-denaturating lysis buffer, 
proteins were extracted from the beads with Laemmli sample buffer and subjected to 
Western blot analysis. 
Table 9 Non-denaturating lysis buffer for immunoprecipitations 
Non-denaturating lysis buffer 
Tris/HCl 300 mM
NaCl 5 mM
EDTA 1 mM
Triton-X100 1%
Complete® 4.0 mM
PMSF 1.0 mM
Na3VO4 1.0 mM
NaF 1.0 mM
H2O 
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2.3.3 Membrane fractionation 
HUVEC lysates were separated into a soluble (cytosolic) and a particulate 
(membranous) fraction, as described previously by Li H et al.121 HUVECs were treated 
as indicated, washed twice with ice-cold PBS, and homogenized in lysis buffer. Lysates 
were centrifuged at 100,000 g for 1 h. The supernatant (cytosolic fraction) was 
collected. The pellet was washed in lysis buffer containing 1.0 M NaCl and centrifuged 
at 100,000 g for 30 min. The supernatant was discarded and the pellet was solubilized 
with lysis buffer containing 20 mM CHAPS at 4°C for 30 min. After centrifugation at 
100,000 g for 1 h, the supernatant was kept as membranous fraction. The 
membranous fraction was used for Western blotting. 
Table 10 Buffer for membrane fractionation 
Membrane lysis buffer 
Tris/HCl, pH 7.5 0.05 M
EDTA 0.5 M
EGTA 0.5 M
Glutathione 0.7 M
Glycerol 10%
H2O 
PMSF 1.0 mM
Complete® 4 mM
 
2.3.4 Extraction of nuclear proteins 
For nuclear preparation, HUVECs were treated as indicated and washed twice with ice-
cold PBS. The PBS was removed completely and cells were lysed by adding 400 μl 
nuclear extraction buffer A. Cells were scraped off the plate/dish and transferred to 1.5 
ml reaction tubes. Cells were allowed to swell on ice for 15 min. Nonidet P-40 (0.625%) 
was added, followed by 10 s of vigorous vortexing. Probes were centrifuged (14,000 
rpm, 1 min, 4°C), supernatants removed, and pellets incubated for 30 min under 
agitation at 4°C in 40 μl nuclear extraction buffer B. After centrifugation (14,000 rpm, 5 
min, 4°C), supernatants were collected and frozen at -80°C. Protein concentrations 
were determined by Bradford assay. 
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Table 11 Extraction buffers for nuclear proteins 
Extraction Buffer A   Extraction Buffer B  
HEPES, pH 7.9 10 mM  HEPES, pH 7.9 20 mM
KCl 10 mM  NaCl 0.4 mM
EDTA 0.1 mM  EDTA 0.1 mM
EGTA 0.1 mM  EGTA 0.1 mM
DTT 1.0 mM  DTT 1.0 mM
PMSF 0.5 mM  PMSF 0.5 mM
   Glycerol 25%
2.4 Western blot analysis 
2.4.1 Protein quantification  
In order to employ equal amounts of proteins in all samples for Western blot analysis, 
protein concentrations were determined using either the Bicinchoninic Protein Assay or 
Bradford Assay. After measurement, protein concentration was adjusted by adding 
Laemmli sample buffer (1x) or 1x SDS sample buffer.  
 
2.4.1.1 Bicinchoninic (BCA) Protein Assay  
Bicinchoninic (BCA) Protein Assay (BC Assay reagents, Interdim, Montulocon, France) 
was performed as described previously.122 10 μl protein samples were incubated with 
200 μl BC Assay reagent for 30 min at 37°C. Absorbance of the blue complex was 
measured photometrically at 550 nm (Tecan Sunrise Absorbance reader, TECAN, 
Crailsheim, Germany). Protein standards were obtained by diluting a stock solution of 
bovine serum albumin (BSA, 2 mg/ml). Linear regression was used to determine the 
actual protein concentration of each sample. 
 
2.4.1.2 Bradford Assay 
Bradford Assay (Bradford solution, Bio-Rad, Munich, Germany) was performed as 
described previously.123 It employs Coomassie Brillant Blue as a dye, which binds to 
proteins. 10 μl protein samples were incubated with 190 μl Bradford solution (1:5 
dilution in water) for 5 min. Thereafter, absorbance was measured photometrically at 
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592 nm (Tecan Sunrise Absorbance reader, TECAN, Crailsheim, Germany). Protein 
standards were achieved as described above (BCA Assay). 
 
2.4.2 SDS-PAGE 
Proteins were separated by discontinuous SDS-polyacrylamid gel electrophoresis 
(SDS-PAGE) according to Laemmli.124 Equal amounts of protein were loaded on 
discontinuous polyacrylamide gels, consisting of a separation and stacking gel, and 
separated using the Mini-PROTEAN 3 electrophoresis module (Bio-Rad, Munich, 
Germany). The concentration of RotiphoreseTM Gel 30 (acrylamide) in the separating 
gel was adjusted for an optimal separation of the proteins depending on their molecular 
weights. Electrophoresis was carried out at 100 V for 21 min for protein stacking and 
200 V for 45 min for protein separation. The molecular weight of proteins was 
determined by comparison with the prestained protein ladder PageRulerTM. 
Table 12 Acrylamide concentration in the separation gel 
Protein Acrylamide 
concentration
phospho-MLC2, di-phospho-MLC2 15%
phospho-p38, phospho-JNK, phospho-ERK, phospho-VE-cadherin, 
ICAM-1, β-actin, TRAF2, TRAF5, cIAP1, cIAP2, XIAP, IκBα, 
phospho-IκBα 
10%
 
Separation gel 10%/15%   Stacking gel   
RotiphoreseTM Gel 30 33.3/5%  RotiphoreseTM Gel 30 40%
Tris (pH 8.8) 375 mM  Tris (pH 6.8) 125 mM
SDS 0.1%  SDS 0.1%
TEMED 0.1%  TEMED 0.2%
APS 0.05%  APS 0.1%
H2O  H2O  
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Table 13 Electrophoresis buffer 
Electrophoresis buffer  
Tris 4.9 mM
Glycine 38 mM
SDS 0.1%
H2O  
 
2.4.3 Tank electroblotting 
After protein separation, proteins were transferred onto a nitrocellulose membrane 
(Hybond-ECLTM, Amersham Bioscience, Freiburg, Germany) by electro tank blotting.125 
A blotting sandwich was prepared in a box filled with 1x tank buffer to avoid bubbles as 
follows: cathode–pad–blotting paper–separating gel (from SDS-PAGE)–nitrocellulose 
membrane–blotting paper–pad–anode. The membrane was equilibrated with 1x tank 
buffer 15 minutes prior to running the tank blot. Sandwiches were mounted in the Mini 
Trans-Blot® system (Bio-Rad, Munich, Germany), ice-cold 1x tank buffer filled the 
chamber and a cooling pack was inserted to avoid excessive heat. Transfers were 
carried out at 4°C, 100 V for 90 min. 
Table 14 Tank blotting buffer 
5x Tank buffer  1x Tank buffer 
Tris base 240 mM  5x Tank buffer 20%
Glycine 195 mM  Methanol 20%
H2O  H2O 
 
2.4.4 Protein detection 
Prior to the immunological detection of the relevant proteins, unspecific protein binding 
sites were blocked. Therefore, the membrane was incubated in non-fat dry milk powder 
(Blotto) 5% or BSA 5% for 2 h at room temperature. Afterwards, detection of the 
proteins was performed by incubating the membrane with the respective primary 
antibody at 4°C overnight (Table 15). After three washing steps with PBS containing 
0.1% Tween (PBS-T), the membrane was incubated with the secondary antibody, 
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followed by 3 additional washing steps. All steps regarding the incubation of the 
membrane were performed under gentle agitation. In order to visualize the proteins, 
two different methods have been used depending on the labels of the secondary 
antibodies. 
 
2.4.4.1 Enhanced chemiluminescence 
Membranes were incubated for 2 h with HRP-conjugated secondary antibodies (Table 
15). For detection, luminol was used as a substrate. The membrane was incubated 
with ECL (enhanced chemiluminescence) solution for 1 minute (ECL Plus Western 
Blotting Detection Reagent RPN 2132, GE Healthcare, Munich, Germany). The 
appearing luminescence was detected by exposure of the membrane to an X-ray film 
(Super RX, Fuji, Düsseldorf, Germany) and subsequently developed with a Curix 60 
Developing system (Agfa-Gevaert AG, Cologne, Germany).  
 
2.4.4.2 Infrared imaging 
Secondary antibodies coupled to IRDyeTM 800 and Alexa Fluor® 680 with emission at 
800 and 700 nm, respectively, were used. Membranes were incubated for 1 h. Protein 
bands of interest were detected using the Odyssey imaging system (Li-COR 
Biosciences, Lincoln, NE). Secondary antibodies used for this type of protein detection 
are listed in (Table 16). 
Table 15 Primary anitbodies 
Antigen Source Dilution In Provider 
β-actin Mouse monocl. 1:1,000 Blotto 1% Chemicon 
IκBα Rabbit polycl. 1:1,000 Blotto 1% Cell Signaling 
phos.-IκBαS32 Rabbit polycl. 1:1,000 Blotto 1% Santa Cruz 
phos.-MLC2S19 Rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
phos.-MLC2T18/S19 Rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
MLC2 Rabbit polycl. 1:500 Blotto 5% Santa Cruz 
phos.-TAK1 T184/Y187 Rabbit monocl. 1:1,000 BSA 5% Cell Signaling 
phos.-p38T180/Y182 Rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
phos.-JNKT183/Y185 Mouse monocl. 1:500 BSA 5% Cell Signaling 
TRAF2 Rabbit polycl. 1:1,000 Blotto 5% Cell Signaling 
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Antigen Source Dilution In Provider 
TRAF5 Mouse monocl. 1:200 Blotto 5% Cell Signaling 
cIAP1 Goat polycl. 1:1,000 Blotto 5% Epitomics 
cIAP2 Rabbit monocl. 1:500 BSA 5% R&DSystems 
XIAP Mouse monocl.  1:1,000 Blotto 5% BD Bioscience 
phos.-VE-cad.Y731 Rabbit polycl. 1:1,000 BSA 3% Biosource 
MKP-1 Rabbit polycl. 1:1,000 Blotto 5% Santa Cruz 
phos.-ERKT202/Y204 Rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
 
Table 16 Secondary antibodies 
 
2.5 Electrophoretic mobility shift assay (EMSA) 
2.5.1 Binding reaction and electrophoretic separation 
The oligonucleotide for NFκB with the consensus sequence 5’-AGT TGA GGG GAC 
TTT CCC AGG C-3’ was purchased from Promega. Using the T4 polynucleotide kinase 
the oligonucleotides were 5’ end-labeled with [γ-32P]-ATP. Equal amounts of nuclear 
protein (1-2 µg) were incubated with 2 μg poly(dIdC) and 3 μl of freshly prepared 
reaction buffer for 10 min at room temperature. The binding reaction was started by 
adding 1 μl of the radioactive-labeled oligonucleotide and carried out for 30 min at 
Antibody Dilution in Provider 
Goat anti-mouse IgG1: HRP 1:1,000 Blotto 1% Biozol 
Goat anti mouse IgG: HRP 1:1,000 Blotto 1% Southern 
Biotechnology 
Goat anti-rabbit: HRP 1:1,000 Blotto 1% Dianova 
Alexa Fluor® 680 Goat anti-mouse IgG 1:10,000 Blotto 1% Molecular Probes 
Alexa Fluor® 680 Goat anti-rabbit IgG 1:10,000 Blotto 1% Molecular Probes 
IRDyeTM 800CW Goat anti-mouse IgG 1:20,000 Blotto 1% LI-COR 
Biosciences 
IRDyeTM 800CW Goat anti-rabbit IgG 1:20,000 Blotto 1% LI-COR 
Biosciences 
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room temperature. The protein-oligonucleotide complexes were separated by gel 
electrophoresis (Power Tec™ HC, BioRad) with 0.25 x TBE buffer at 100 V for 60 
minutes using non-denaturating polyacrylamide gels (5% PAA, 20% glycerol). After 
electrophoresis, gels were exposed to Cyclone Storage Phosphor Screens (Canberra-
Packard, Schwadorf, Austria) for 24 hours, followed by analysis with a phosphor 
imager station (Cyclone Storage Phosphor System, Canberra-Packard).  
Table 17 Buffers and gels for EMSA 
5x Binding Buffer  Loading Buffer  
Tris/ HCl 50 mM  Tris/HCl 250 mM
NaCl 250 mM  Glycerol 40%
MgCl2 5.0 mM  Bromphenolblue 0.2%
EDTA 2.5 mM   
Glycerol 20%   
 
Reaction buffer  10x TBE, pH 8.3  
5x binding buffer 90%  Tris 890 mM
Loading buffer 10%  Boric acid 890 mM
DTT 2.6 mM  EDTA 20 mM
  H2O 
 
Non-denaturating PAA gels 4.5% 
10 x TBE 5.3%
RotiphoreseTM Gel 30 15.8%
Glycerol 2.6%
TEMED 0.05%
APS 0.08%
H2O 
 
2.6 Flow cytometry 
Flow cytometry has been used for the analysis of intercellular adhesion molecule-1 
(ICAM-1) expression and for the quantification of apoptosis rate. All measurements 
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were performed on a FACSCanto II (Becton Dickinson, Heidelberg, Germany). Cells 
were illuminated by a blue argon laser (488 nm). 
 
2.6.1 Analysis of ICAM-1 expression on cell surface 
Cells were seeded in 24-well plates and grown to confluence and treated as indicated 
in the respective figure legends. Cells were washed with PBS twice, harvested by 
trypsination, and fixed in PBS/4% formalin for 10 min. Afterwards, cells were washed 
with PBS and 0.5 µg FITC-labeled CD54/ICAM-1 antibody (Biozol, Eching, Germany) 
was added for 45 min at RT. Cells were washed with PBS and 10,000 cells were 
measured by flow cytometry to detect the membrane expression of ICAM-1 as 
evidenced by a median shift in fluorescence intensity. 
  
2.6.2 Determination of cell surface expression of CD11b 
Granulocytes (106 cells/ml, 100 µl) were incubated with ABT 30 minutes before 
activating in HEPES buffer (pH 7.4) them for 15 min with fMLP (10-7 M). Then, cells 
were fixed with 4% formaldehyde and washed with PBS followed by incubation with 
saturating concentrations of FITC-labeled antibody against CD11b for 45 minutes at 
room temperature. Cells were washed once with PBS, resuspended in PBS and 
analyzed by flow cytometry. At least 5,000 events were acquired. 
Table 18 Antibodies used for flow cytometry 
Specificity Format Isotype Dilution Provider 
CD11b FITC monocl. antibody 1:20 AbD Serotec 
ICAM-1 FITC monocl. antibody 1:25 BIOZOL 
 
2.6.3 Determination of ROS production in granulocytes 
ROS production in granulocytes was assessed by measuring the intracellular oxidation 
of dihydrorhodamine (DHR) to rhodamine. Therefore, the granulocytes (106 cells/ml, 
100 µl) in suspension were primed with DHR (1 µM) for 10 min at 37°C. Afterwards 
cells were incubated with ABT for 30 min and activated with fMLP (10-7 M) for 15 min. 
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The reaction was stopped on ice and the DHR oxidation was analyzed by flow 
cytometry. At least 5,000 events were acquired. 
 
2.6.4 Quantification of apoptotsis rate 
Cell cycle analysis and quantification of apoptosis rate was performed according to 
Nicoletti et a.126 based on the fact that endonucleases, which are activated in apoptotic 
processes, cause DNA fragmentation. Therefore, an increasing subdiploid DNA 
content of cells indicates the induction of apoptosis. Cells were seeded in 24-well 
plates, grown to confluence and treated as indicated. After 24 h, or 48 h cells were 
trypsinized, washed three-times with PBS, and centrifugated at 600 g and 4°C for 10 
min. For permeabilization and staining, cells were incubated in fluorochrome solution 
(FS) buffer containing propidium iodide (PI) to detect the DNA content of the cells. After 
incubation at 4°C overnight cells were analyzed by flow cytometry. 
Table 19 FS buffer for Nicoletti assay 
FS buffer  
Na3-citrate 0.1%
Triton-X 100 0.1%
PBS  
 
2.7 Transfection of cells 
For transient transfection with the indicated siRNA and plasmids, respectively, 
HUVECs were electroporated using the Nucleofector® II device in combination with the 
HUVEC Nucleofector® Kit (both from LONZA Cologne AG, Cologne, Germany). 
 
2.7.1 Transfection with siRNA 
In order to silence XIAP, HUVECs were transiently transfected with XIAP siRNA. XIAP 
On-TARGETplus SMARTPool siRNA consisting of four different siRNA sequences was 
used (Dharmacon, Lafayette, CO, USA). On-TARGETplus siCONTROL non-targeting 
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siRNA was used as a control. siRNAs were suspended in Dharmacon 1x siRNA buffer, 
aliquoted and stored at -80°C. The concentration of siRNA was verified using a 
NanoDrop (Wilmington, DE, USA). For each transfection, 2 x 106 HUVECs were 
suspended in 100 μl HUVEC Nucleofector Solution and added to 3 µg of the respective 
siRNA. 
Table 20 On-TARGETplus SMARTPool XIAP siRNA 
XIAP siRNA Target sequence (5´-3´) Provider 
1 GUAGAUAGAUGGCAAUAUG Dharmacon 
2 GAACUGGGCAGGUUGUAGA  
3 GAAAGAGAUUAGUACUGAA  
4 GGACUCUACUACACAGGUA  
 
The mixture of cells and siRNA was transferred to a cuvette and transfection was 
performed (program A-034). Immediately after electroporation, 900 μl of prewarmed 
culture medium was added to the cuvette. Afterwards, cells were seeded into 24-well 
(500,000 cells per well) for FACS and Western blot analysis. 
 
2.7.2 Transfection with plasmids 
For the NFκB reporter assay, HUVECs were transiently transfected with the plasmids 
pGL4.32[luc2P/NF-κB-RE/Hygro] and pGL4.74[hRluc/TK] (both Promega, Mannheim, 
Germany) in the ratio 1:10. For each transfection, 1 x 106 HUVECs were suspended in 
100 μl HUVEC Nucleofector Solution and added to 0.5 µg or 5 µg of the respective 
plasmid. Electroporation was performed in analogy to the siRNA experiments. After 
transfection, cells were seeded into 96-well plates. Experiments were performed 16 h 
after transfection. 
 
2.8 Dual Luciferase® Reporter Assay System 
The reporter construct pGL4.32[luc2P/NF-κB-RE/Hygro], a firefly luciferase reporter 
gene containing five copies of an NFκB response element (NFκB-RE) (Promega, 
Mannheim, Germany) and a plasmide coding for Renilla reniformis luciferase with 
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thymidine kinase (TK) promoter (pGL4.74[hRluc/TK] (Promega, Mannheim, Germany) 
used as a transfection control were co-transfected in the ratio of 1:10 by electroporation 
employing the Amaxa HUVEC Nucleofector kit (Amaxa GmbH, Koeln, Germany). 
Transfected 80,000 HUVECs per well were seeded in 96-well plates. After 24 h they 
were pretreated with the appropriate substances for 30 min followed by an incubation 
with TNFα for 6 h. The luciferase activity was determined using the Dual-Luciferase® 
Reporter Assay System (Promega, Mannheim, Germany). Cells were washed with 
PBS and, in order to lyse the cells, 20 µl 1x passive lysis buffer (PLB) (1 x PLB diluted 
1:5 from 5 x PLB, Promega, Mannheim, Germany) per well was added. After freezing 
the plates at -80 °C they were allowed to thaw under agitation for 15 min. The 
luciferase activity was determined in white 96 well plates using a luminometer (Berthold 
Orion II, Berthold Detection Systems, Pforzheim, Germany). The firefly luciferase 
reporter is measured by adding 100 µl Luciferase Assay Reagent II per well (LAR II) 
(injector 1) to generate a luminescent signal lasting at least one minute. After 
quantifying the firefly luminescence, this reaction is quenched, and the Renilla 
luciferase reaction is initiated simultaneously by adding 100 µl Stop & Glo® Reagent 
(injector 2) to the same sample. The luminometer was programmed to perform a 2-
second measurement delay followed by a 10-second measurement read for both 
luciferase activities. The relative NFκB transactivation activity was assessed as the x-
fold change of firefly luciferase activity after normalization for Renilla reniformis 
luciferase activity. 
2.9 Macromolecular permeability assay 
HMECs (0.125 x 106 cells/well) were seeded on collagen G-coated 12-well Transwell® 
plate inserts (pore size 0.4 µm, polyester membrane; Corning, New York, USA) and 
cultured for 48 h. FITC-dextran (40 kDa; 1 mg/ml; Sigma-Aldrich) was given to the 
upper compartment at t = 0 min. Cells were treated as indicated. Samples were taken 
from the lower compartment at t = 0, 5, 10, 15, 30 min. The fluorescence increase (ex 
485/em 535) of the samples was detected with a fluorescence plate reader 
(SpectraFluor Plus, Tecan Deutschland GmbH). The mean fluorescence of untreated 
cells at t = 30 min was set as 100%. The data are expressed as percent increase of 
fluorescence versus the control. 
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2.10 Confocal microscopy 
A Zeiss LSM 510 META confocal microscope (Zeiss, Oberkochen, Germany) was used 
for obtaining images of the translocation of the p65 subunit of NFκB to the nucleus in 
fixed cells. HUVECs were cultured on ibidi µ-slides (8-well ibiTreat, ibidi GmbH, 
Munich, Germany) until reaching confluence. Afterwards, cells were treated as 
indicated, washed with PBS and fixed with 4% parafomaldehyde in PBS at room 
temperature (10 min), followed by permeabilization via incubation with 0.2% Triton X-
100 (Sigma, Taufkirchen, Germany) in PBS (2 min). Cells were washed and unspecific 
binding was blocked with 0.2% BSA in PBS for 30 min. Afterwards, cells were 
incubated with a primary antibody against p65 (Santa-Cruz Biotechnology Inc., 1:200 in 
0.2% BSA/PBS, rabbit polyclonal) for 1 h at room temperature. After three washing 
steps with PBS, cells were incubated with the AlexaFluor® Goat anti-rabbit secondary 
antibody (Invitrogen, 1:400 in 0.2% BSA) for 45 min at room temperature. Finally, the 
slides were again washed three times with PBS (5 min) and embedded in PermaFluor 
mounting medium (VWR, Darmstadt, Germany). 
 
2.11 Leukocyte adhesion assay 
2.11.1 Adhesion assay 
HUVECs were seeded in 24-well plates and grown to confluence. They were treated 
with appropriate concentrations of ABT for 30 min before incubation with TNFα for 24 h. 
The medium was discarded and 105 freshly isolated granulocytes per well were added 
in a total volume of 500 µl of granulocyte medium. The granulocytes (see 2.2.5) were 
allowed to adhere for 30 min. Then the wells were washed 3 times with PBS+ to 
remove non-adherent cells. After washing 100 µl of lysis buffer (Table 21) per well was 
added and the plates were incubated for 30 min at 37°C.  
2.11.2 Myeloperoxidase (MPO) activity  
The amount of adhered neutrophils was analyzed by spectrometric measurement of 
the activity of the myeloperoxidase (MPO, an enzyme mainly occurring in neutrophils): 
100 µl of MPO substrate was added to 100µl of each lysate. The conversion of the 
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substrate was determined at 540 nm using SPECTRAFluor Plus plate reader. The 
number of adhered granulocytes was calculated from the gradient of the conversion 
curve of dianisidine. 
Table 21 Buffer and medium for granulocyte adhesion assay 
Phosphate buffer (pH 6.0)  Granulocyte medium 
KH2PO4 9.08 g/l  M 199 500 ml
Na2HPO4 11.88 g/l  FCS 10 ml
H2O  Antibiotics 3.5 ml
   
MPO substrate  Lysis buffer 
Dianisidine 0.06%  HTAB 
(Hexadecyltrimethylammonium 
bromide) 
1%
H2O2 0.0009%  Phosphate buffer (pH 6.0) 
Phosphate buffer (pH 
6.0) 
  
 
2.12 In vivo assays 
2.12.1 Animals 
Male C57BL/6 mice were purchased from Charles River (Sulzfeld, Germany). All 
experiments were performed with male mice at the age of 10-12 weeks. Animals were 
housed under conventional conditions with free access to food and water. All 
experiments were performed according to German legislation for the protection of 
animals and approved by the local government authorities. 
 
2.12.2 Murine antigen-induced arthritis. 
The antigen-induced arthritis experiment was performed as previously described by 
Veihelmann et al.127 On day -21 and -14 C57BL/6 mice were subcutaneously 
immunized against methylated bovine serum albumine (mBSA) (Sigma-Aldrich, 
Deisenhofen, Germany) containing Freund´s complete adjuvant and supplemented 
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with heat-killed Mycobacterium tuberculosis strain H37RA (Difco, Augsburg, Germany) 
in the left flank (day -21) and in the right flank (day -14). Simultanously, the mice were 
injected intraperitoneally with heat killed Bordetella pertussis (2 x 109) (Institute of 
Microbiology, Berlin, Germany). On day 0, the mice were injected with mBSA into the 
left knee joint to cause arthritis. The right knee joint was treated with saline as an 
internal control. One part of the mice (six animals) was treated daily with 
intraperitoneally administered ABT (50 µg per animal, diluted in PBS) The control group 
(five animals) was treated with the corresponding concentration of DMSO. The knee 
joint diameters, i.e. the transverse diameter of the knee joint measured by a caliper in 
units of 0.1 mm, were recorded from day -2 until the end of the experiment. 
 
2.12.3 Analysis of leukocyte adhesion and transmigration by intravital 
microscopy of mouse creamaster muscle 
This assay was kindly performed by Dr. Markus Rehberg from the group of Prof. Dr. 
Fritz Krombach, Walter-Brendel-Centre of Experimental Medicine, University of 
Munich, Germany. 
The recruitment of leukocytes in the cremaster muscle of mice was induced by an intra-
scrotal injection of recombinant murine TNFα (500 ng per mouse) 4 h prior to intravital 
microscopic observation. 
The surgical preparation was performed as originally described by Baez et al. with 
minor modifications.128 Mice were anesthetized using a ketamine/xylazine mixture (100 
mg/kg ketamine and 10 mg/kg xylazine). The right cremaster muscle was opened 
ventrally in a relatively avascular zone and spread over the transparent pedestal of a 
custom-made microscopic stage. Throughout the procedure as well as after surgical 
preparation during in vivo microscopy, the muscle was superfused with warm-buffered 
saline. In each animal, at least five single unbranched postcapillary venules with 
diameters of 17.5 to 35 µm were analyzed. During a 15 min observation period, 
leukocyte rolling, adhesion and transendothelial migration were assessed by near-
infrared reflected light oblique transillumination microscopy. Videotaped images were 
evaluated off-line using CAPIMAGE software (Zeintl, Heidelberg, Germany). Leukocyte 
rolling flux fraction is defined as the flux of rolling leukocytes in percent of total 
leukocyte flux. The total number of adherent leukocytes was determined for each 
venule segment (100 µm) and is expressed per 104 µm2 of venule surface area. 
Emigrated cells were counted in an area reaching out 75 µm to each side of a vessel 
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over a distance of 100 µm vessel length and are presented per 1.0×104 µm2 tissue 
area. Centerline blood flow velocity was measured by using intra-arterial-administered 
microspheres (0.96 µm; FluoSpheres; Invitrogen). The wall shear rate [s-1] was 
estimated as 8 x [Vb /d], where Vb refers to the mean blood flow velocity and d to the 
diameter of the vessel. Mean blood flow velocity, Vb, was approximated by multiplying 
the centerline blood flow velocity with 0.625129. The number of leukocytes in whole 
blood was determined at the end of each experiment using Coulter ACT Counter 
(Coulter Corp. Miami, FL, USA). 
2.12.4 Statistical analysis 
The number of independently performed experiments is stated in the respective figure 
legend. One representative image is shown. Bar graph data are mean values ± SE. 
Statistical analysis was performed with the GraphPad Prism software version 3.03 
(GraphPad Software, San Diego, CA, USA). Unpaired t test was used to compare two 
groups. To compare three or more groups, one-way ANOVA followed by Bonferroni 
post hoc test was used. Values of P < 0.05 were considered statistically significant. 
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3.1 ABT abolishes antigen-induced arthritis in mice and 
inhibits leukocyte transmigration in vivo 
Besides the interaction of IAPs with caspases, it is known that IAPs play a role in TNFR 
and NFκB signaling7, 23 which led us to the hypothesis that IAPs are involved in 
inflammatory processes and therefore IAP antagonists might have an anti-inflammatory 
potential. We applied an antigen-induced arthritis mouse model to elucidate whether 
ABT shows anti-inflammatory effects in a clinically relevant in vivo model. Mice were 
immunized against methylated bovine serum albumin (mBSA). After immunization, 
arthritis was induced in one of the both knee joints. In contrast to the control group, 
mice that were medicated subcutaneously with 50 µg ABT per day before and after 
induction of arthritis did not evolve any joint swelling in the mBSA-treated knee as 
depicted in Figure 9A.  
Furthermore, to specifically investigate the in vivo action of ABT on endothelial 
activation and leukocyte endothelium interaction, we analyzed the TNFα-induced 
leukocyte rolling and adherence by intravital microscopy of the mouse cremaster 
muscle. The group of mice that was pretreated intraarteriously with 0.5 µg ABT showed 
a slight reduction of leukocyte adhesion and significant decrease in leukocyte 
transmigration in comparison to the control group (Figure 9B). The blood flow velocity, 
the leukocyte shear rate, and the total count of leukocytes were not influenced by ABT 
(data not shown).  
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Figure 9 ABT inhibits inflammatory processes in vivo. A) For the arthritis model, mice 
were immunized with methylated BSA (mBSA). One group of the mice was additionally treated 
with 50 µg ABT/mouse ip. every day beginning two days before the induction of arthritis with 
mBSA in the left knee joint. The right knee joints were used as internal control and were injected 
with NaCl solution. The knee joint diameter was determined daily starting 2 days before the 
induction of the arthritis until the end of the experiment 7 days later. Data are expressed as 
mean ± S.E.M. (control mice: n = 5, ABT-treated mice n = 6). *, p ≤ 0.05 versus TNFα. B) 
Leukocyte transmigration is impaired by ABT in vivo. Leukocyte extravasation in the cremaster 
muscle was induced by intra-scrotal injection of recombinant murine TNFα (500 ng) 4 h prior to 
intravital microscopic observation. The mice of the one group were injected intra-arteriously with 
0.5 µg ABT/mouse 30 min before application of TNFα, the control group was treated with PBS. 
During a 15 min observation period, leukocyte adhesion and trans-endothelial migration were 
assessed. Data are expressed as mean ± S.E.M. (control mice: n = 5, ABT-treated mice: n = 5). 
*, p < 0.01 versus TNFα. This assay was performed by Dr. Markus Rehberg from the group of 
Prof. Dr. Fritz Krombach, Walter-Brendel-Centre of Experimental Medicine, University of 
Munich, Germany 
 
 
 
In summary, ABT potently inhibits antigen-induced arthritis and reduces leukocyte 
transmigration in vivo. Moreover, ABT was well tolerated in intra-peritoneal as well as 
in intra-arterial application. 
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3.2 ABT does not exert proapototic effects in HUVECs 
The endothelium plays an important role in inflammatory processes.79 Since the IAP 
antagonist shows anti-inflammatory effects in vivo we aimed at analyzing the actions of 
ABT on activated endothelial cells and uncovering the role of IAPs in inflammatory 
processes of endothelial cells in vitro. Because synthetic Smac mimetics are applied to 
induce apoptosis in cancer cells it was necessary to determine possible pro-apoptotic 
effects of the Smac mimetic ABT in endothelial cells. The treatment with ABT in 
concentrations ranging from 1 nM to 1 µM did not evoke apoptosis (subdiploid DNA 
content) in HUVECs after 24 h or 48 h (Figure 10A). There also was no induction of 
apoptosis detectable in cells that were pretreated with ABT (3 nM to 3 µM) before they 
were exposed to TNFα for 24h (Figure 10B). 
These results indicate that the IAP antagonist ABT does not induce apoptosis in 
HUVECs, neither alone nor in combination with TNFα. 
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Figure 10 ABT does not induce apoptosis in HUVECs. Confluent cells were treated with 
the indicated concentrations of ABT for 24 h or 48 h (A) or they were pretreated with ABT for 30 
min before incubation with TNFα for 24 h (B). After harvesting of the cells they were stained 
with PI and the subdiploid DNA content was determined by FACS analysis. Data are expressed 
as mean ± S.E.M. (n = 3).  
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3.3 Influence of ABT on endothelial barrier function 
The anti-inflammatory potential of the IAP antagonist in vivo gave rise for the 
exploration of effects of the IAP inhibitor and of the role of IAPs in inflammation-
activated endothelial cells in vitro. Since the loss of endothelilal barrier function is a 
hallmark of inflammatory processes,80 we investigated if ABT has any impact on 
endothelial barrier function. 
 
3.3.1 ABT inhibits macromolecular hyperpermeability 
The endothelial macromolecular permeability was induced by thrombin and analyzed 
by a Transwell® assay. While the treatment of endothelial cells with thrombin increases 
their permeability to macromolecules, the pretreatment of the cells with ABT resulted in 
a clear reduction of thrombin-induced endothelial hyperpermeability (Figure 11). 
 
 
 
 
Figure 11 ABT restores endothelial barrier function. Macromolecular permeability of 
HMECs was measured by a Transwell® assay. The cells were seeded on Transwell® inserts and 
treated with thrombin (1 U/ml) after 30 min of preincubation with ABT (1 µM). FITC-labeled 
dextran was used as a tracer and added to the upper compartment of the transwell chamber. 
After 5, 10, 15 and 30 min, the amount of FITC-dextran in the lower compartment of the 
chamber was determined. Data are expressed as mean ± S.E.M. (n = 7). *, p < 0.5 versus 
thrombin.  
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3.3.2 Impact of ABT on adhesion junctions and the contractile machinery of 
endothelial cells 
Endothelial barrier function is maintained by the balance between contractile and 
adhesive forces.80 Therefore, we analyzed if ABT affects the contractile machinery or 
the endothelial adhesion junctions. There was no difference detectable in the thrombin-
induced MLC2-phosphorylation irrespective of whether HUVECs were preincubated 
with ABT or not. In contrast, the thrombin-triggered phosphorylation of VE-cadherin 
was attenuated when cells were treated with ABT (Figure 12). Thus, the IAP antagonist 
seems not to influence the thrombin-induced activation of the contractile apparatus, but 
the signal initiating the destruction of adhesion junctions was decreased by the Smac 
mimetic. 
 
 
 
 
 
Figure 12 Influence of ABT on key parameters of endothelial barrier function. HUVECs 
were incubated with 1 µM ABT before treatment with 1 U/ml thrombin for 5 min or 15 min. The 
phosphorylation of MLC2 and of VE-cadherin was analyzed by Western blot analysis. (n = 3). 
 
 
 
 
ABT abrogates thrombin-induced hyperpermeability and influences the adhesion 
junctions in terms of abrogating the VE-cadherin phosphorylation but does not inhibit 
MLC2 activation. 
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3.4 Effects of ABT on leukocyte adhesion to endothelial cells 
Adapted from our in vivo findings that ABT impairs the endothelial leukocyte 
interactions, we investigated the impact of the IAP antagonist on TNFα-induced 
adhesion of leukocytes to endothelial cells. The adhesion of neutrophil granulocytes to 
endothelial cells was reduced concentration dependently when the HUVECs were 
exposed to the IAP antagonist before treatment with TNFα (Figure 13).  
The impairment of leukocyte adhesion to HUVECs could even be amplified when both, 
the neutrophils and the HUVECs, were treated with ABT (data not shown).  
 
 
 
Figure 13 ABT influences the adhesion of leukocytes to HUVECs. HUVECs were seeded 
in 24-well plates and preincubated for 30 min with ABT (100 nM, 500 nM and 1 µM) and after 
that treated with TNFα (10 ng/ml) for 24 h. Human neutrophil granulocytes were added (105 
cells per well) and allowed to adhere for 45 min. MPO (an enzyme specific for granulocytes) 
activity was measured to determine the amount of adhered neutrophil granulocytes. Data are 
expressed as mean ± S.E.M. (n = 7). *, p < 0.05 versus TNFα. 
 
ABT decreases the TNFα-induced adhesion of leukocytes to endothelial cells and in 
this regard affects endothelial cells as well as leukocytes. 
 
3.4.1 Influence of ABT on CD11b expression and oxidative burst of neutrophil 
granulocytes 
Since the treatment of granulocytes with ABT additionally affects the interaction 
between granulocytes and HUVECs, we checked if ABT attenuates the activation of 
leukocytes by analyzing two markers for neutrophil activation: the fMLP-induced 
expression of CD11b and the oxidative burst. As depicted in Figure 14A, the treatment 
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of neutrophil granulocytes with ABT did not interfere with their property to execute 
oxidative burst. In contrast, the expression of the integrin CD11b was reduced when 
granulocytes were incubated with ABT (Figure 14B). 
 
A 
 
B 
 
 
Figure 14 ABT does not affect oxidative burst of neutrophil granulocytes but reduces 
CD11b expression. Human neutrophil granulocytes were treated for 30 min with ABT (100 nM 
and 1 µM) before incubation with 10-7 M fMLP for 15 min. A) For the determination of the 
oxidative burst by FACS analysis, the granulocytes were preincubated with 10 µM 
dihydrorhodamine before the treatment with ABT and TNFα. B) The expression of CD11b on 
the granulocyte cellsurface was examined by staining with a CD11b antibody following FACS 
analysis. Data are expressed as mean ± S.E.M. (n = 3). *, p < 0.05 versus TNFα. 
 
These results suggest that the IAP antagonist does not influence the granulocyte 
activation regarding their cytotoxic functions. It seems to selectively influence the cell 
surface expression of adhesion molecules. 
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3.5 Role of IAPs in TNFα-induced adhesion molecule 
expression 
Because the treatment of endothelial cells with ABT affected the adhesion of 
granulocytes, we investigated the influence of ABT on endothelial activation. Therefore, 
we analyzed the endothelial cell surface expression of intercellular adhesion molecule-
1 (ICAM-1), which is involved in the firm adhesion of leukocytes to endothelial cells and 
the following diapedesis into the underlying tissue.92, 120 
 
3.5.1 ABT reduces TNFα-induced expression of an endothelial adhesion 
molecule 
The expression of ICAM-1 was induced by TNFα and analyzed by flow cytometry. ABT 
impaired TNFα-induced expression of ICAM-1 on the cell surface of HUVECs 
dependently on the used concentrations (Figure 15A). Also the total cellular amount of 
ICAM-1 was disminished by treating the endothelial cells with ABT as indicated by 
Western blot analysis (Figure 15B). 
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Figure 15 ABT reduces ICAM-1 expression in HUVECs. A) In order to investigate the 
TNFα-induced expression of the adhesion molecule ICAM-1 on HUVECs, they were 
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preincubated with ABT (100 pM–1 µM) for 30 min and then treated with TNFα (10 ng/ml) for 24 
h. The levels of ICAM-1 on the cell surface were determined by flow cytometry. Data are 
expressed as mean ± S.E.M. (n = 3). *, p < 0.05 versus TNFα. B) For the Western blot analysis 
of the total cellular amount of ICAM-1, HUVECs were treated for 6 h with TNFα (10 ng/ml) after 
pretreatment with ABT. 
 
3.5.2 The IAP inhibitors Smac066 and Smac085 are capable of reducing TNFα-
induced expression of ICAM-1 
To ensure that the effects of ABT on the inflammatory activation of endothelial cells 
arise from targeting the IAPs and to exclude off-target effects of ABT, we compared its 
influence on the TNFα-evoked adhesion molecule expression with the structurally 
different IAP antagonists Smac066 and Smac085 (figure 17).68, 120 Similar results were 
obtained for the monovalent Smac mimetic Smac066 and the homodimeric Smac 
mimetic Smac085 as for ABT regarding the reduction of TNFα-evoked ICAM-1 
expression (Figure 16), suggesting that molecules that mimic the interaction of Smac 
with IAPs have an anti-inflammatory potential. 
 
 
 
 
Figure 16 Influence of Smac066 and Smac085 on ICAM-1 expression. HUVECs were 
treated with Smac066 or Smac085 (100 nM-1 µM) for 30 min before incubation with TNFα (10 
ng/ml) for 24 h. The levels of ICAM-1 on the cell surface were determined by flow cytometry. 
Data are expressed as mean ± S.E.M. (n = 3). *, p < 0.05 versus TNFα. 
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Figure 17 Structurally different Smac mimetics. ABT (A410099.1) Oost et al.6 and 
Smac066 (compound 40d) Seneci et al.120 The structure of Smac085 is unpublished. 
 
3.5.3 Impact of the pan-caspase inhibitor Q-VD-OPh on ICAM-1 expression 
induced by TNFα 
Smac mimetics have originally been designed to abrogate the inhibitory interaction of 
IAPs with caspases.68 Therefore, we tested if the activation of caspases participates in 
the effect of ABT on the TNFα-induced ICAM-1 expression. The application of a pan-
caspase inhibitor had no impact on the ABT-mediated reduction of expression of ICAM-
1 on endothelial cells (Figure 18), indicating that the ICAM-reducing effect of ABT is 
independent of caspases 
 
 
 
Figure 18 The role of caspases in the ABT-induced reduction of ICAM-1 expression. Cells 
were preincubated with the pan-caspase inhibitor Q-VD-OPh (QVD) (10 µM, 30 min) to examine 
the role of caspases before treating them with ABT (100 nM) for 30 min and TNFα (10 ng/ml) for 
24 h. The ICAM-1 expression on HUVECs was analyzed by flow cytometry. Data are means ± 
S.E.M. (n = 3). *, p < 0.05 versus TNFα. 
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Taken together, our results clearly suggest that Smac mimetics influence the 
interactions between leukocytes and endothelial cells by reducing the endothelial 
adhesion molecule expression. Moreover, the prevention of endothelial activation as a 
result of targeting IAPs by Smac mimetics is not due to an activation of caspases and 
points to a considerable role of IAPs in the context of inflammatory processes. 
 
3.6 Interactions of ABT with the NFκB signaling 
Since the activation of the transcription factor NFκB is involved in the TNFα-induced 
increase of adhesion molecule expression119, we consequentially explored the 
influence of ABT on different stages of NFκB activation.  
 
3.6.1 ABT does not influence phosphorylation and degradation of IκBα  
ABT did neither reduce the TNFα-induced phosphorylation of the IKK inhibitor IκBα nor 
did it result in a degradation of IκBα (Figure 19).  
 
 
Figure 19 ABT does not significantly influence NFκB activation. The phosphorylation and 
the degradation of IκBα was induced by incubating the cells with 10 ng/ml TNFα for 15 min, 30 
min and 60 min after they were treated with ABT (100 nM) for 30 min. The levels of IκBα and 
phospho-IκBα were examined by analysis blot (n=3). 
 
3.6.2 The translocation of p65 is not impaired by ABT 
In accordance to these findings, the TNFα-induced translocation of the NFκB p65 
subunit to the nucleus was not influenced by ABT (Figure 20). 
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Figure 20 The translocation of the NFκB p65 subunit is not affected by ABT. For 
immunocytochemistral analysis of the translocation of the p65 subunit to the nucleus, cells were 
treated with TNFα (10 ng/ml) for 15 min, 30 min and 60 min following to a 30 min preincubation 
with ABT (100 nM) (n = 3). 
 
3.6.3 ABT does not affect the DNA-binding capacity of NFκB 
Moreover, the IAP antagonist did not interfere with the increase in the DNA-binding 
capacity of NFκB evoked by TNFα (Figure 21). The DNA-binding capacity of NFκB is 
neither reduced by ABT after short term treatment nor after long term treatment of the 
endothelial cells with TNFα (data not shown). 
 
 
 
 
 
Figure 21 ABT does not influence DNA-binding capacity of NFκB in electrophoretic 
mobility shift assay (EMSA). In order to determine the effect of ABT on DNA-binding capacity of 
NFκB, HUVECs were treated with ABT (100 nM or 1 µM) for 30 min followed by TNFα (10 
ng/ml, 15 min and 30 min). Nuclear proteins were isolated. P32-labeled NFκB consensus 
sequence oligonucleotides were added and an electrophoretic mobility shift assay was 
performed (n = 3). 
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3.6.4 NFκB-dependent promoter activity is not influenced by ABT 
Since ABT did not influence the NFκB activation cascade, we finally checked impact of 
ABT on the transcriptional activity of NFκB dependent genes. The NFκB reporter gene 
assay indicated no significant effect of ABT on NFκB-dependent promoter activity 
(Figure 22). 
 
 
 
 
Figure 22 ABT does not attenuate the NFκB promoter activity. For the Dual Luciferase® 
NFκB reporter assay, HUVECs were transfected with plasmids coding for Renilla luciferase 
(determination of transfection efficiency) and firefly luciferase (coupled to NF-κB promotor). 16 h 
after transfection ABT (100 nM to 1 µM) was added and 30 min later cells were treated with 
TNFα (10 ng/ml) for 6 h (left digram). Curcumin (20 µM) in combination with TNFα was used as 
a positive control (right diagram). The luciferase activity was assayed by spectrofluorometry. 
Data are expressed as means ± S.E.M. (n = 3). 
 
 
 
Summarizing the results from above, ABT does not significantly affect the TNFα- 
induced activation cascade of NFκB. 
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3.7 Interactions of ABT with MAPK signaling 
Since the ABT-dependent reduction of TNFα-induced ICAM-1 expression is not due to 
an effect on NFκB signaling, we analyzed if the anti-inflammatory effect of ABT on 
endothelial cells is based on an interaction with the proinflammatory MAPK signaling. 
 
3.7.1 ABT affects TNFα-induced activation of MAPKs 
Figure 23 shows that ABT diminished the TNFα-induced phosphorylation of the MAPKs 
p38 and JNK that both are known to participate in pro-inflammatory signaling. In 
contrast, the IAP antagonist had no impact on the TNFα-mediated phosphorylation of 
ERK1. The protein levels of the MAPK phosphatase MKP-1 were not altered by ABT as 
well. 
 
 
 
Figure 23 ABT influences the TNFα-induced activation of MAPKs. HUVECs were 
incubated with 100 nM ABT for 30 min before treating them with 10 ng/ml TNFα for 5, 15, 30 
and 60 min. Levels of phospho-JNK, phospho-p38, phospho-ERK and MKP-1 were determined 
via Western blot (n = 3). 
 
3.7.2 Inhibition of p38 and JNK influence ICAM-1 expression 
To test whether the anti-inflammatory effect of ABT is based on the inhibition of the 
p38-and JNK activity, the influence of the p38 inhibitor SB203580 and the JNK inhibitor 
SB600125 on the TNFα-evoked ICAM-1 expression on HUVECs was analyzed. The 
treatment of the cells with the p38- as well as with the JNK inhibitor resulted in a 
significant decrease of TNFα-induced ICAM-1 expression (Figure 24). The effect of 
SP600125 was more pronounced than the impact of SB203580. The added levels of 
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ICAM-1 reduction caused by SB203580 and by SP600125 correspond to the effect of 
ABT on TNFα-induced ICAM-1 expression. 
 
 
 
 
Figure 24 The influence of a p38- and a JNK inhibitor on the expression of ICAM-1. The 
cells were incubated with the SB203580 (20 µM), SP600125 (10 µM), or with ABT (100 nM) for 
30 min and for another 24 h with TNFα (10ng/ml). Levels of ICAM-1 expression were 
determined by flow cytometry. Data are expressed as mean ± S.E.M. (n = 3). *, p < 0.05 versus 
TNFα. 
 
3.7.3 ABT controls the activity of the MAP3K TAK1 
Due to the inhibitory impact of the IAP antagonist on the activation of p38 and JNK, we 
analyzed the interaction of ABT with the MAPK signaling cascade upstream of JNK and 
p38. The MAP3K TAK1 is phosphorylated immediately upon activation by TNFα. This 
phosphorylation was reduced when cells were pretreated with the IAP antagonist as 
shown in Figure 25. 
 
 
 
 
Figure 25 ABT reduces the phosphorylation of TAK1. The activation of the MAP3K TAK1 
was determined by Western blot analysis after preincubation of HUVECs with ABT (100 nM and 
1 µM, 30 min) and following treatment with TNFα (10 ng/ml, 5 min) (n = 3). 
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3.7.4 Impact of ABT on the interactions of TAK1 binding protein (TAB1) with 
XIAP 
The activation of TAK1 can (among others) be influenced by the interaction between 
the BIR1 domain of XIAP and TAK1 via the TAK1 binding protein TAB1 7. Smac, the 
intrinsic IAP antagonist, is able to affect the interaction of XIAP and TAB1.7 Immuno-
precipitations of TAB1 with following Western blot analysis of co-precipitated XIAP 
indicated that the interaction of XIAP and TAB1 in HUVECs is very weak in contrary to 
cancer cells (data not shown). Neither ABT nor TNFα nor a combination of both 
influenced the amount of XIAP that is co-precipitated with TAB1 (Figure 26). 
 
 
 
 
 
Figure 26 ABT does not influence the XIAP-TAB1 interaction. Cells were pretreated with 
ABT (1 µM, 30 min) and incubated with 10 ng/ml TNFα for 5 min. TAB1 was immune-
precipitated and the amount of co-precipitated XIAP was detected by Western blot analysis (n = 
3). 
 
 
 
Taking together all results from above, ABT strongly reduces the TNFα-induced 
activation of the MAPKs p38 and JNK which are involved in the TNFα-evoked 
expression of ICAM-1 but not by an increase of MKP-1 levels. The activity of the 
upstream MAP3K TAK1 was also affected by the IAP antagonist, while this effect 
seems not to be based on an abrogation of the interaction between XIAP and TAK1.  
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3.8 Silencing of XIAP does not reduce ICAM-1 expression 
ABT is modeled on the basis of the interaction of the endogenous IAP antagonist Smac 
with the BIR3 domain of XIAP. Because of this fact and the finding that ABT does not 
block the activation of TAK1 by an abrogation of the interaction of XIAP with TAB1 we 
investigated the role of XIAP for the anti-inflammatory impact of ABT. 
We tested if the down-regulation of XIAP levels results in similar effects on ICAM-1 
expression as treating the cells with the IAP-antagonist. Unexpectedly, silencing of 
XIAP in HUVECs did not cause a reduction of ICAM-1 expression but even increased it 
as shown in Figure 27A. Moreover, in cells where XIAP was down-regulated, ABT still 
was capable of reducing TNFα-caused ICAM-1 expression. The Western blot analysis 
exhibited a clear reduction of XIAP protein levels in those cells that were transfected 
with XIAP siRNA, while at the same time cIAP1 and cIAP2 protein levels were 
significantly up-regulated (Figure 27B). 
 
A  B 
 
 
Figure 27 Silencing of XIAP does not reduce ICAM-1 expression. XIAP was silenced in 
HUVECs by XIAP siRNA. 24 h after transfection of cells with XIAP siRNA or non-targeting 
siRNA, the respectively cells were exposed to ABT (100 nM, 30 min) and to TNFα (10 ng/ml, 24 
h). The ICAM-1 expression was determined by flow cytometry. Data are expressed as mean ± 
S.E.M. (n = 3). XIAP protein levels and the content of cIAP1 and cIAP2 were studied by 
Western blot analysis.  
 
The presence of XIAP is not required for the anti-inflammatory impact of the IAP 
antagonist. Instead, the reduction of XIAP levels in endothelial cells induces a 
counteraction in terms of an increased cIAP1 and cIAP2 expression. 
0
1.0
2.0
3.0
IC
AM
-1
 e
xp
re
ss
io
n
[x
-fo
ld
in
cr
ea
se
]
4.0
TNFα
ABT
nt-siRNA XIAP-siRNA
--
actin
cIAP2
cIAP1
XIAP
nt-
siRNA
XIAP-
siRNA
3  RESULTS 70 
  
 
3.9 Interactions of ABT with the TNF receptor signaling 
Since ABT does not influence the TAK1 activation by inhibiting the interaction of XIAP 
and TAB1 and since silencing of XIAP does not cause any anti-inflammatory effect in 
HUVECs, the question raised in which way the Smac mimetic influences the pro-
inflammatory activation of the MAPKs.  
 
3.9.1 ABT induces degradation of cIAP1 and cIAP2 
The analysis of XIAP and cIAP1 protein levels showed a very fast and long lasting 
reduction of cIAP1 levels in endothelial cells treated with ABT. In contrast, the amount 
of XIAP remained constant as it is known for the cellular IAP antagonist Smac75 (Figure 
28A). The protein levels of cIAP2 are only detectable if its expression is activated by 
TNFα as described by Harlin et al.26 They appear to be similarly influenced by ABT as 
cIAP1 levels (Figure 28B). 
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Figure 28 Degradation of cIAP1 and cIAP2 induced by ABT. Cells were treated with ABT 
(100 nM) for 1 min, 3 min, 5 min, 10 min or 15 min (A) or cells were incubated with ABT (100 
µM) before treatment with TNFα (10 ng/ml) (B). The effect of ABT on the total cellular levels of 
XIAP, cIAP1 and cIAP2 was determined by Western blot analysis (n = 3). 
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3.9.2 The proteasomal degradation of cIAP1 and cIAP2 is responsible for the 
anti-inflammatory effect of ABT 
Because of the knowledge that cIAP1 and cIAP2 participate in TNF receptor signaling12 
we investigated if their downregulation caused by ABT is responsible for the reduction 
TNFα-evoked signs of inflammation. The degradation of cIAP1 and cIAP2 activated by 
ABT was inhibited by the proteasome inhibitor MG132 as shown in Figure 29A. The 
analysis of the TNFα-induced ICAM-1 expression showed that abolishing the 
proteasomal activity by MG132 abrogates the attenuating effect of ABT on the 
expression of ICAM-1 (Figure 29B). 
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Figure 29 Inhibition of the proteasome abrogates the anti-inflammatory effect of ABT. In 
order to analyze the involvement of proteasomal degradation the HUVECs were preincubated 
with the proteasome inhibitor MG132 (10 µM, 30 min) before treatment with ABT (1 µM) for 30 
min and TNFα (10 ng/ml) for 24 h. The levels of cIAP1, cIAP2 and XIAP were determined by 
Western blot analysis (A) and the ICAM-1 expression on HUVECs was analyzed by flow 
cytometry (B). Data are mean values of ± S.E.M. (n = 3). *, p < 0.05 versus TNFα. 
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3.9.3 Influence of ABT on the participants of the TNFR1-associated complex 
TRAF2 and TRAF5 
In order to investigate the role of the ABT-induced proteasomal degradation of cIAP1 
and cIAP2 in the inflammation-inducing signaling of TNFα, we analyzed the influence 
of the IAP antagonist on TRAF2, a member of the TNF receptor associated signaling 
complex. TRAF2 mediates the activation of NFκB and of the MAP3K (TAK1) 
signaling61 and it is known to interact with cIAP1 and cIAP2 in the TNFR1-associated 
complex64. Upon treatment of endothelial cells with ABT, the levels of TRAF2 in the 
membrane fraction (where the TNF receptor associated signaling complex is located) 
decreased immediately. In contrast, the amount of TRAF5, which is known to 
compensate the loss of TRAF2 only in terms of activation of the NFκB signaling, 130, 131 
remained constant (Figure 30). 
 
 
 
 
Figure 30 ABT influences the amount of TRAF2 but not of TRAF5 in the membrane 
fraction. Western blot analysis of the membrane fractionation of HUVECs pretreated with ABT 
(1 µM, 30 min) and exposed to 10 ng/ml TNFα for 5 min shows the amount of TRAF2, TRAF5 
and cIAP1 in the membrane fraction (n = 3). 
 
 
Our data strongly indicate an as yet unknown role of cIAP1 and cIAP2 in the TNFα-
induced inflammatory signaling of endothelial cells. Moreover, they evidence an impact 
of ABT on these signaling processes by influencing TRAF2 in the TNFR-associated 
signaling complex. 
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4.1 The link between IAPs and inflammation 
Activation of inflammatory processes is crucial for the host defense against infections 
or for repairing tissue damage, but it shows destructive properties in pathologies like 
atherosclerosis or sepsis or in ischemic tissue. The administration of conventional anti-
inflammatory drugs is not always effective and may often cause undesirable side 
effects. Therefore, inflammation is still a very important subject of research in terms of 
unraveling signaling interconnections to reveal new therapeutical strategies.  
Since the transcription factor NFκB regulates the expression of adhesion molecules 
and cytokines in inflammatory processes as well as the expression of anti-apoptotic 
genes like IAPs or Bcl-2, inflammation and the regulation of cell death are often closely 
connected.132 For example, the up-regulation of IAPs in atherosclerotic plaques of 
patients with carotid stenosis seems to be involved in the stabilization of symptomatic 
atheromatous plaques by preventing apoptosis.133  
Cancer as well is associated with inflammatory processes. On the one hand 
inflammatory diseases increase the risk of many types of cancer134 and on the other 
hand inflammatory cells and cytokines are present in the microenvironment of many 
tumors from the early stages of development.135  
Despite these associations between inflammation and cancer, and the fact that XIAP is 
known to activate NFκB signaling7 as well as that cIAP1 and cIAP2 participate in 
TNFR1-associated signaling,23, 64 current research is only illuminating the role of IAPs 
in TNFR and NFκB signaling concerning apoptotic processes.  
In our work, we for the first time demonstrate that targeting IAPs has the potential of a 
completely new and promising anti-inflammatory approach. 
4.2 Anti-inflammatory effects of ABT in vivo 
Until now, IAP antagonists have only been applied in tumor models to proof them as 
promising candidates for cancer therapy.68 ABT, for example, was effectively used in a 
breast cancer xenograft tumor model.6 This is for our best knowledge the first study 
investigating the effects of an IAP antagonist in vivo in an inflammatory context. 
Rheumathoid arthritis (RA), the most common form of arthritis, concerns millions of 
people world wide and is associated with chronic pain and reduced quality of life.136 It is 
a process of chronic inflammation and involves the infiltration of neutrophils, monocytes 
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and lymphocytes into the inflamed tissue. The infiltration of joints results in synovial 
proliferation, pannus formation, cartilage destruction and subchondral bone erosion.137 
The antigen-induced arthritis in mice is a well established model for the investigation of 
RA.138 We found a highly potent action of ABT on mBSA-induced arthritis: a complete 
abrogation of knee joint swelling, elucidating for the first time an anti-inflammatory 
potential of an IAP antagonist in a clinically relevant in vivo model. 
The activated endothelium is a crucial player in the process of arthritis because it 
facilitates the transit of more and more leukocytes to the inflamed tissue, which is also 
supported by an increased angiogenesis.136 Thereby, cytokines like TNFα activate the 
endothelium to express a large amount of the adhesion molecules ICAM-1 and E-
selectin as found in the synovial tissue of arthritic patients. Elevated expression of 
adhesion molecules on neutrophils had been demonstrated as well.139  
The convincing protective effect of ABT in a model of a disease that crucially involves 
endothelium leukocyte interactions encouraged us to pass on to the detailed analysis 
of the influence of ABT on these interactions in vivo by intravital microscopy of the 
mouse cremaster muscle. The significant ABT-dependent abrogation of the leukocyte 
transmigration indicated an effect of the IAP antagonist on the leukocyte endothelium 
interaction and on the activation of the leukocytes and/or the endothelium.  
Thus, we for the first time showed a promising anti-inflammatory action of an IAP 
antagonist in vivo, which called for a detailed analysis of the underlying mechanisms on 
inflammation-activated cells in vitro. 
4.3 Effects of ABT on endothelial activation in vitro 
4.3.1 Functional in vitro assays 
Under normal physiological circumstances, the vascular endothelium exhibits a 
quiescent phenotype that modulates permeability, coagulation and vasodilation. 
However, when the endothelium is exposed to inflammatory mediators derived from a 
local infection, the endothelium becomes activated to a state that expresses 
chemokines and adhesive receptors facilitating the recruitment of pro-inflammatory 
leukocytes. The influence of the IAP antagonist on this state was investigated by 
several functional assays. 
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4.3.1.1 Endothelial permeability  
Inflammatory cytokines and the process of leukocyte transmigration activate 
endothelial cells in terms of weakening the endothelial barrier function and lead to an 
increase of endothelial permeability. Thus, endothelial hyperpermeability is a hallmark 
of inflammatory processes and seriously assists the progression of the disease when it 
gets down to an excessive extravasation of fluid and leukocytes to the tissue. A total 
collapse of endothelial barrier function, like in sepsis, contributes to its life-threatening 
complications.88,90,89 
The strong barrier protective effect of ABT indicates that the IAP antagonist 
counteracts endothelial activation in vitro. The abrogation of the thrombin-induced 
hyperpermeability seems not to rely on an influence of ABT on the contractile 
machinery but on a prevention of adhesion junction disassembly, indicated by a 
reduction of VE-cadherin phosphorylation. These data are in line with our in vivo 
findings regarding the ABT-mediated abrogation of leukocyte transmigration because 
the phosphorylation of VE-cadherin is required in the diapedesis process of leukocytes 
through the endothelial cell monolayer.96, 140, 141  
Although a participation of IAPs in TNFR signaling is known, it is totally unknown how 
IAPs are involved in the thrombin-mediated activation of endothelial cells or how an 
IAP antagonist could interfere with endothelial hyperpermeability activated by the 
thrombin receptor PAR. Hence, it would be a very interesting task to investigate the link 
between the IAPs and the PAR receptor signaling and to analyze possible effects of 
ABT on keyregulators of endothelial barrier function (RhoA, Rac1, Ca2+ signaling, 
PKA/cAMP, PKC and the cytoskeleton). This project is currently pursued. 
 
4.3.1.2 ICAM-1 mediated endothelium leukocyte interactions 
The inflammatory activation of endothelial cells induces, besides barrier dysfunction, 
the upregulation of adhesion molecules and mediates the leukocyte endothelium 
interactions.92 The attenuation of ICAM-1 expression attests the IAP antagonist to have 
an anti-inflammatory potential in vitro by preventing TNFα-mediated endothelial 
activation. Since ICAM-1 is engaged in the firm adhesion- and the diapedesis-step of 
leukocyte transmigraton,141, 142 the ICAM-1 reducing effect of ABT explains the 
attenuation of neutrophil adhesion to endothelial cells in vitro as well as the inhibition of 
leukocyte transmigration in vivo. This effect might also contribute to the impact of ABT 
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on antigen-induced arthritis because a strong increase in ICAM-1 expression is 
reported to be vital for the disease progression in arthritis.136  
Moreover, the influence of ABT seems not to be limited on endothelial activation. It also 
appears to act on the adhesive properties of leukocytes as the additional reduction of 
leukocyte adhesion to the endothelium indicates when the leukocytes as well (not only 
the endothelial cells) were treated with the Smac mimetic. This is supported by our 
finding of a reduction of the ICAM-1-interacting adhesion molecule CD11b on ABT 
treated neutrophils. Since the activation of leukocytes employs similar signaling 
pathways (for example regarding the TNFR1 signaling and the engagement of MAPK 
signaling) as endothelial activation,143 supposably the IAPs also play a role in leukocyte 
activation. Uncovering the participation of IAPs in the inflammatory activation of 
leukocytes and the contribution of the ABT-mediated attenuation of this activation to 
the impairment of leukocyte recruitment constitutes an interesting field of research. 
However, in order to investigate the signaling mechanisms that underly the influence of 
ABT on endothelial activation and to uncover the role of IAPs in inflammation we 
concentrated our research activities on endothelial cells. 
 
The IAP antagonist attenuates the inflammatory activation of endothelial cells by two 
means: It stabilizes endothelial barrier functions and prevents endothelial adhesion 
molecule expression which protects from leukocyte endothelium interactions. 
4.3.1.3 Specifity of the ICAM-1-attenuating effect of ABT 
Since ABT is designed on the model of the interaction between Smac and the BIR3 
domain of XIAP6 it is rather unlikely that the IAP antagonist exerts its anti-inflammatory 
effects by the inhibition of other targets than IAPs. Though off-target effects can not be 
ruled out completely, the parallel effects of structurally completely different IAP 
antagonists on the TNFα-activated ICAM-1 expression allayed the concerns and 
underlined the role of IAPs in inflammatory events.  
The intention for the design of Smac mimetics was to kill cancer cells by activating 
caspases.6, 120, 144 In endothelial cells, there was no induction of apoptosis detectable by 
ABT. Even in the combination with TNFα, which is reported to be necessary to 
sensitize some cancer cell lines for IAP antagonist-mediated apoptosis, ABT did not 
increase cell death. This might be due to the fact that endothelial cells are in 
comparison to cancer cells not highly active and proliferative cells and therefore react 
differently to death-propagating stimuli. Our findings ensured that the anti-inflammatory 
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effects of the IAP antagonist are not due to an induction of apoptotic processes and 
indicated that the role of IAPs in endothelial cells must exceed the regulation of cell 
death.  
Besides acting in apoptosis, caspases can be involved in inflammatory processes. As 
participants of the inflammasome, the caspases 1, 4, and 5 contribute to the maturation 
of cytokines.145 Moreover, Wu et al. described a connection of the caspases-3 and -8 
and inflammatory activation of endothelial cells, in particular in the TNFα-mediated 
ICAM-1 expression.146 However, we could clearly exclude that the anti-inflammatory 
effect of ABT is due to an influence on caspase activity pointing to a different signaling 
mechanism for the anti-inflammatory effect of ABT. 
 
Our functional in vitro assays indicate that the IAP antagonist attenuates inflammatory 
activation of endothelial cells by two means: It stabilizes endothelial barrier functions 
and prevents endothelial adhesion molecule expression which protects from leukocyte 
endothelium interactions. 
In summary, our in vivo findings and the functional in vitro assays regarding the 
endothelial activation for the first time characterize an IAP antagonist as a potent anti-
inflammatory drug and indicate a participation of IAPs in the inflammatory activation of 
endothelial cells. The exclusion of apoptosis or caspases as mediators of the anti-
inflammatory effect of ABT favors the assumption that the IAP antagonist exerts its 
effects via influencing the TNFR or NFκB signaling.  
4.3.2 Signaling 
On the basis of the effects of ABT on endothelial activation, we investigated the 
signaling mechanisms underlying the protective impact of ABT and the role of IAPs in 
inflammation-activated endothelial cells. 
4.3.2.1 NFκB/MAPK signaling 
So far, the existing data about the function of IAPs in endothelial cells only refer to the 
aspect that IAPs, as NFκB dependent genes, protect endothelial cells from TNFα-
induced apoptosis.147, 148 
Interestingly, the activation of the pro-inflammatory transcription factor NFκB is not the 
major target of the anti-inflammatory action of ABT in endothelial cells. This is 
somewhat surprising because on the one hand, NFκB is one of the main responsible 
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transcription factors for the TNFα-induced expression of the adhesion molecule ICAM-
1,119 and on the other hand, it is described that IAPs are involved in the TNFα-
mediated activation of NFκB.12, 68 However, the reported effects of IAP antagonists on 
NFκB signaling are not coincident. It is referred that the autoubiquitination-dependent 
loss of cIAP1 and cIAP2 induced by IAP antagonists does not influence11 or completely 
abrogates NFκB signaling,56, 58 while others found that degradation of cIAP1 and cIAP2 
activated by a Smac mimetic stimulates NFκB signaling.59, 149 Nevertheless, we found 
in HUVECs that not the NFκB signaling but the activation of the MAPKs p38 and JNK 
is attenuated by ABT. JNK and p38 are crucial mediators of TNFα signaling and 
strongly involved in the regulation of cellular adhesion molecules such as ICAM-113 as 
we were able to demonstrate in our cell system as well. By the activation of pro-
inflammatory transcription factors, namely of AP-1, but also ATF-2, CREB, SP-1, 
STAT-1 and STAT-3, they contribute to driving the expression of ICAM-1.13, 119 
Moreover, p38 is known to be involved in endothelial activation and enhances 
neutrophil recruitment.141 Corresponding to the inhibition of p38 and JNK, the IAP 
antagonist blocks the activation of the upstream MAP3K TAK1, which is regulated by 
TNFR signaling and by XIAP. TAK1 is a MAP3K for p38 and JNK but not for ERK, 
whose activity was accordingly not influenced by ABT. The finding that ABT does not 
influence the levels of the MAPK phosphatase MKP-1, which is responsible for the 
deactivation of MAPKs, also points towards an ABT-mediated inhibition of TAK1 and its 
upstream signaling. 
For that reason we propose that an inhibition of IAPs in inflammation-activated 
endothelial cells blocks cellular adhesion molecule expression for the most part via an 
inhibition of the MAPK signaling.  
4.3.2.2 Role of XIAP 
XIAP is known to mediate the activation of TAK1 by its interaction with TAB1. Thus, the 
most obvious explanation for the influence of ABT on TAK1 activation would be the 
interruption of the interaction between XIAP and TAB1 as it is described for the cellular 
IAP antagonist Smac.7 However, the interaction of XIAP and TAB1 in HUVECs seems 
to be very weak in contrast to cancer cells (data not shown) and moreover the IAP 
antagonist did not influence this interaction. Furthermore, silencing of XIAP did not 
result in an inhibition of endothelial activation. In contrast, it even increased TNFα-
induced ICAM-1 expression. Importantly, downregulation of XIAP went along with a 
rise of cIAP1 and cIAP2 levels. A compensatory up-regulation of cIAP1 and cIAP2 has 
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also been reported for XIAP knockout mice.26 These findings led us to the presumption 
that XIAP is at least not the main target of the IAP antagonist in the inflammatory 
context even though the IAP antagonist was modeled to the BIR3 domain of XIAP. 
Therefore, XIAP does not seem to play a predominant role in the inflammatory 
activation of endothelial cells but cIAP1 and cIAP2 might be of importance.  
Furthermore, the results regarding the XIAP silencing also point out that the 
downregulation of a protein by silencing does not always have to be in accordance with 
the interactions of an inhibitor with this protein. Silencing results in the disappearance 
of the target protein and can result in an upregulation of functionally related proteins 
(as cIAP1 and cIAP2 upon silencing of XIAP). An inhibitor for example may just inhibit 
a special function of the protein but the protein is still present (like XIAP). Thus, the 
protein is still able to interact with other proteins via structurally not influenced sites. 
Moreover, the inhibitor can influence special functions of the protein like the 
ubiqitination processes of cIAP1 and cIAP2. Therefore, it is not trivial to compare 
findings in literature that were achieved by silencing or overexpression of XIAP, cIAP1 
and cIAP2 or by using a Smac mimetic. Since IAP antagonists mimic the actions of the 
cellular protein Smac, they are valuable tools for the investigation of the role of IAPs by 
comprising the complex interplay of the IAPs. 
4.3.2.3 Role of cIAP1 and cIAP2 
ABT mediates the loss of cIAP1 and cIAP2 but not of XIAP as it is described for other 
IAP antagonists that were designed to mimic the Smac AVPI-binding motif and target 
the XIAP-BIR3 domain. These IAP antagonists not only interact with XIAP but also 
exhibit high affinities to cIAP1 and cIAP2,69 which triggers of the proteasomal 
degradation of cIAP1 and cIAP2.26, 59, 74 Our results evidence that the anti-inflammatory 
effect of ABT does not necessarily arise from antagonizing XIAP but results from the 
loss of cIAP1 and cIAP2 because the ICAM-1 reducing effect of the Smac mimetic was 
reversible by inhibition of the proteasome. This notion is supported by the fact that 
cIAP1 and cIAP2 upregulation that results from XIAP silencing increases the 
proinflammatory activation of the endothelium. Moreover, we found that the reduction 
of cIAP1 and cIAP2 protein levels influences TNF receptor signaling which 
consequently alters the activation of the MAP3K TAK1.12 
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4.3.2.4 TNFR-associated signaling 
The TNFα-induced activation of TNFR1 involves the assembly of the TNFR1-
associated signaling complex containing TRAF2 and cIAP1/2. The ubiquitination 
activity of cIAP1 and cIAP2 is essential for the recruitment and the activation of the 
IKK/NEMO and the TAB/TAK complex.12, 106 Via their BIR1 domain cIAP1 and cIAP2 
directly interact with the adaptor protein TRAF2,64 which participates in NFκB as well 
as in MAPK signaling.8, 74, 150, 151 In our experiments the treatment of HUVECs with an 
IAP antagonist resulted in a proteasome-dependent degradation of cIAP1 and cIAP2 
and we detected a loss of TRAF2 in the membrane fraction. This result led us to the 
assumption that the degradation of cIAP1 and cIAP2 influences the TNFα-induced 
MAPK activation by affecting TRAF2 in the TNFR1-associated signaling complex and 
leaves the question why NFκB signaling is not affected. Yeh et al. reported that a loss 
of TRAF2 prevents TNFα-caused activation of JNK.130 In contrast to the levels of 
TRAF2, the amount of TRAF5 in the membrane fraction was not changed. TRAF5 is 
reported to compensate the absence of TRAF2 concerning the activation of the NFκB 
signaling by TNFα while MAPK signaling is impaired.130, 131 This supports our 
hypothesis that the loss of cIAP1 and cIAP2 in the TNFR associated signaling complex 
goes along with an impaired TRAF2-mediated initiation of MAPK signaling and explains 
why the inflammatory activation of endothelial cells is abrogated, although NFκB 
signaling is not affected.  
Our findings point toward an important role of cIAP1 and cIAP2 in inflammation. 
Unfortunately, a cIAP1 and cIAP2 double knockout mouse that could reflect the effects 
of ABT still doesn´t exist. cIAP1 or cIAP2 knockout mice are, beside an increased 
susceptibility of macrophages to LPS-induced apoptosis, asymptomatic. This is 
presumably due to the fact that for each cIAP knockout the corresponding cIAP is up-
regulated and each cIAP can compensate for the other cIAP because of their 
redundant functions.152, 153  
 
Altogether, this study not only demonstrates for the first time that IAPs play an 
important regulatory role in inflammatory processes of endothelial cells but also 
highlights a clear anti-inflammatory potential of an IAP antagonist in vitro and in vivo. 
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The IAPs are in the focus of current recent research regarding their role in apoptotic 
processes and in tumor progression. IAP antagonists are not only promising new 
therapeutic substances but, moreover, serve as important tools for the investigation of 
IAP-mediated signaling in apoptosis.  
The human IAPs, XIAP, cIAP1 and cIAP2, not only interact with caspases but also 
participate in TNFR and NFκB signaling. The NFκB and TNFR signaling is, besides its 
involvement in the regulation of cell death, vital for the inflammatory activation of 
endothelial cells, a prerequisite and fundament of many common and life-threatening 
pathologies like atherosclerosis, arthritis, diabetes or sepsis. Since there is still a need 
for efficient treatments of these diseases, it is necessary to dig deeper into the 
investigation of the underlying signaling mechanisms and to search for new appropriate 
targets. 
Interestingly, despite the importance of NFκB and TNFR signaling in inflammation, the 
role of IAPs in these signaling pathways is only elucidated concerning apoptotic 
processes. Our hypothesis was that IAPs are crucial mediators of inflammation and 
that therefore IAP antagonists should exhibit an anti-inflammatory potential. 
To uncover the link between IAPs and inflammation we applied the IAP antagonist A-
410099.1 (ABT) and investigated its role in inflammatory processes. 
We, for the first time, demonstrated profound anti-inflammatory actions of an IAP 
antagonist in vivo in an antigen-induced arthritis mouse model as well as the 
prevention of leukocyte extravasation in mice.  
Functional in vitro assays showed an ABT-mediated attenuation of endothelial 
hyperpermeability and a reduced leukocyte adhesion to TNFα-activated endothelial 
cells accompanied by an abrogation of the expression of the endothelial cell adhesion 
molecule ICAM-1.  
Mechanistically, we found that ABT does not influence endothelial NFκB signaling, but 
decreased the TNFα-induced activation of the pro-inflammatory MAPK signaling 
cascade consisting of the MAP3K TAK1 and the MAPKs p38 and JNK. The activity of 
p38 and JNK was shown to be involved in TNFα-mediated ICAM-1 expression. 
Most importantly, ABT seems not to exert its anti-inflammatory effect by an inhibition of 
XIAP but by the induction of the proteasomal degradation of cIAP1 and cIAP2. The 
downregulation of cIAP1 and cIAP2 affects the TNF receptor-associated signaling 
upstream of the MAPKs and NFκB in terms of a reduction of the levels of TRAF2. This 
presumably accounts for the inhibition of the MAPKs, while the activation of the NFκB 
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signaling might be compensated by TRAF5, whose levels were not influenced by the 
loss of cIAP1 and cIAP2 (Figure 31). 
 
 
 
Figure 31 Effects of ABT on TNFα-induced inflammatory signaling in endothelial cells. 
 
 
 
 
 
In conclusion: 
1. We, for the first time, discovered a profound anti-inflammatory potential of an 
IAP antagonist in vivo and in vitro.  
2. Our work highlights IAPs as regulators in inflammatory processes, i.e.: in 
leukocyte endothelium interactions and of endothelial activation. 
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Atrial natriuretic peptide (ANP), a hormone firstly found to be produced in the cardiac 
atria, plays a role in the regulation of natriuresis, diuresis and vasodilation and 
therefore contributes to cardiovascular homeostasis. In the last years it has been 
shown that diverse tissues express receptors for ANP or produce ANP. For example 
several components of the immune system are influenced by ANP like 
polymorphonuclear cells, macrophages or the endothelial cells.154 The endothelium is, 
besides its functions in cardiovascular homeostasis, an important player in the 
regulation of immune response in inflammatory processes. Kiemer et al. found that 
ANP reduces inflammation–induced activation of endothelial cells.155 Moreover, a 
protective effect on the endothelial barrier function of TNFα-activated endothelial cells 
was reported.156 
Since the underlying molecular mechanisms of the barrier protective effect of ANP 
were not known, we aimed at investigating the actions of ANP on histamine-induced 
hyperpermeability. 
At first we proofed that ANP significantly inhibits vascular leakage in vivo. Our in vitro 
assays demonstrated that ANP modulates the barrier disrupting effects of histamine by 
an inhibition of adhesion junction disassembly and by a reduction of cell contraction. 
Moreover, we could determine the receptor subtype by which the ANP-caused barrier 
protective effects were mediated  
Thus, our results highlighted ANP as a barrier-protecting agent that directly targets key 
regulators of endothelial permeability and therefore might open a novel therapeutic 
strategy for inflammatory diseases. 
This study was completed in 2007 and published in 2008 as an accelerated 
communication in Mol Pharmacol.: 
Atrial natriuretic peptide protects against histamine-induced endothelial barrier 
dysfunction in vivo. Robert Fürst, Martin F. Bubik, Peter Bihari, Bettina A. Mayer, 
Alexander G. Khandoga, Florian Hoffmann, Markus Rehberg, Fritz Krombach, Stefan 
Zahler and Angelika M. Vollmar. Mol Pharmacol. 2008;74(1):1-8. 
Recent publications strongly confirm our findings about the barrier protective effect of 
ANP as an inhibitor of the contractile machinery and a protector of adhesion 
junctions.157, 158 
The manuscript of our study is subsequently added. 
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Abstract 
 
Endothelial barrier dysfunction is a hallmark of many severe pathologies including sepsis or 
atherosclerosis. The cardiovascular hormone atrial natriuretic peptide (ANP) has increasingly 
been suggested to counteract endothelial leakage. Surprisingly, the precise in vivo relevance of 
these observations has never been evaluated. Thus, we aimed to clarify this issue and, 
moreover, to identify the permeability-controlling subcellular systems that are targeted by ANP. 
Histamine was used as important pro-inflammatory, permeability-increasing stimulus. 
Measurements of FITC-dextran extravasation from venules of the mouse cremaster muscle and 
rat hematocrit values were performed to judge changes of endothelial permeability in vivo. 
Importantly, ANP strongly reduced the histamine-evoked endothelial barrier dysfunction in vivo. 
In vitro, ANP blocked the breakdown of transendothelial electrical resistance (TEER) induced by 
histamine. Moreover, as judged by immunocytochemistry and Western blot analysis, ANP 
inhibited changes of vascular endothelial (VE)-cadherin, β-catenin, and p120ctn morphology, VE-
cadherin and myosin light chain 2 (MLC2) phosphorylation, and F-actin stress fiber formation. 
These changes seem to be predominantly mediated by the natriuretic peptide receptor (NPR)-
A, but not by NPR-C. In summary, we revealed ANP as a potent endothelial barrier protecting 
agent in vivo and identified adherens junctions and the contractile apparatus as subcellular 
systems targeted by ANP. Thus, our study highlights ANP as an interesting pharmacological 
compound opening new therapeutic options for preventing endothelial leakage. 
 
 
Introduction 
 
The endothelium crucially participates in the regulation of important physiological functions, 
such as blood pressure, coagulation, or host defense, and it represents a barrier that controls 
the passage of cells, macromolecules, and fluid between the blood and the adjacent tissue 
interstitium. Beyond its physiological role, the endothelium is also involved in pathological 
conditions: Endothelial barrier dysfunction is a hallmark of inflammatory processes and still 
poses an important therapeutical challenge, since a causal pharmacological treatment is as yet 
widely lacking. 
Endothelial barrier function is mainly governed by the balance between interendothelial cell 
adhesion. Adherens junctions (AJs) are important subcellular structures responsible for 
endothelial cell-cell attachment and they represent multiprotein complexes that consist of 
vascular endothelial (VE)-cadherin, β-catenin, and p120ctn. Under inflammatory conditions VE-
cadherin junctions disassemble, thus facilitating paracellular passage, and show an increased 
tyrosine phosphorylation. Endothelial cell retraction is caused by the activation of the contractile 
machinery, i.e. the interaction between actin and myosin, which is controlled by phosphorylation 
of the myosin light chain (MLC). These two regulatory systems could be targets of a successful 
therapeutic principle. 
The cardiovascular hormone atrial natriuretic peptide (ANP) is secreted by the cardiac atria as 
response to an increased plasma volume. In general, ANP binds to the guanylate cyclase-
coupled natriuretic peptide receptor (NPR)-A and NPR-C, which lacks guanylate cyclase 
function. ANP exerts a hypotensive effect by its natriuretic, diuretic, and vasodilating action. The 
role of ANP as an important regulator of the cardiovascular system is highlighted by the fact that 
ANP (carperitide, HANP®) has been approved as drug for the treatment of acute heart failure in 
Japan. Recently, however, ANP has been recognized to possess important additional functions 
beyond blood pressure regulation: ANP is expressed by macrophages and is able to influence 
these immune cells by attenuating their inflammatory response (Kiemer and Vollmar, 2001). 
Most importantly, ANP exerts anti-inflammatory properties in the endothelium (Kiemer et al., 
2005). Thus, we posed the working hypothesis that ANP could open new therapeutical options 
for protecting against endothelial barrier dysfunction. In fact, some evidence is given from in 
vitro and ex vivo experiments that ANP influences an inflammation-increased permeability 
(Kiemer et al., 2002a; Lofton et al., 1991; Inomata et al., 1987). However, data precisely 
demonstrating a beneficial effect of administered ANP on inflammation-induced endothelial 
barrier dysfunction in vivo are lacking. Moreover, data concerning the effect of ANP on 
subcellular systems that control permeability are missing. 
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Therefore, aim of the study was (i) to examine the in vivo potential of ANP as pharmacological 
agent counteracting endothelial leakage and (ii) to investigate the influence of ANP on key 
regulators of endothelial permeability, i.e. the endothelial cell adhesion (VE-cadherin) and 
contraction system (MLC). 
 
 
Materials and Methods 
 
Measurement of vascular permeability in the mouse cremaster muscle in vivo. Male 
C57BL/6NCrl mice (Charles River, Sulzfeld, Germany) with 23-25 g bodyweight were used. All 
experiments were performed according to the German legislation for the protection of animals. 
Surgery was performed as described by Baez (Baez, 1973). Vascular permeability was 
analyzed according to Hatekeyama et al. (Hatakeyama et al., 2006). Briefly, mice were 
anesthetized i.p. using a ketamine (Pfizer, Karlsruhe, Germany)/xylazine (Bayer, Leverkusen, 
Germany) mixture. Fluorescein isothiocyanate-dextran (150 kDa, Sigma-Aldrich, Taufkirchen, 
Germany), Ringer solution (control) and ANP (bolus sufficient to reach 200 nM plasma 
concentration, AnaSpec/MoBiTec, Göttingen, Germany) were applied into the left femoral 
artery. 20 min after ANP application, the cremaster was superfused with histamine (30 µM, 
Sigma-Aldrich) for 10 min. Dexamethasone 21-phosphate (disodium salt, Sigma-Aldrich) was 
administered i.p. (10 mg/kg bodyweight) 2 h before histamine. Postcapillary venules with 
diameters of 18-30 µm were analyzed. Ten regions of interests (50x50 µm²) in the interstitial 
tissue (approx. 50 µm distant from the venule) were randomly selected. Intravital microscopic 
images were recorded with an IMAGO S/N 382KLO345 CCD-camera (TILL Photonics, 
Gräfelfing, Germany) and subjected to digital image analysis (TILLvisION 4.0, TILL Photonics). 
 
Measurement of rat hematocrit. Male Sprague-Dawley rats (Charles River) with 190-240 g 
bodyweight were used. All experiments were performed according to the German legislation for 
the protection of animals. Rats were anesthetized i.p. using a fentanyl (Jansen-Cilag, Neuss, 
Germany)/midazolam (Ratiopharm, Ulm, Germany) mixture and anesthesia was maintained by 
1.5% isoflurane (Abbott, Wiesbaden, Germany). Rats were pre-treated for 15 min with ANP 
(bolus sufficient to reach 200 nM plasma concentration) or PBS, followed by histamine (bolus 
sufficient to reach 1 µM plasma concentration). Reagents were applied into the jugular vein. 30 
min after administration of histamine, blood samples were collected via a jugular artery catheter 
and hematocrit was determined by centrifugation in hematocrit capillaries. 
 
Cell culture. Human umbilical vein endothelial cells (HUVECs) were prepared as previously 
described (Kiemer et al., 2002a) and cultured in Endothelial Cell Growth Medium (Provitro, 
Berlin, Germany) containing 10% FBS (Biochrom, Berlin, Germany). Cells were used for 
experiments at passages 1-3. 
 
Measurement of transendothelial electric resistance (TEER). HUVECs were cultured on 
collagen A (Biochrom)-coated Millicell 12 mm PCF inserts (Millipore, Schwalbach, Germany). 
TEER measurements were performed with an Ussing-type chamber. The incubation fluid 
(HEPES-buffer containing 10% FBS) was circulated by means of humidified air streams at 
37°C. A custom-built voltage/current clamp unit in connection with a computer-aided evaluation 
program was used. Bidirectional square current pulses of 50 µA and 200 ms duration were 
applied across the monolayer every 2 second. The resistance of the monolayer was calculated 
by Ohm’s law from the induced deflection of the transendothelial voltage. 
 
Immunocyto/histochemistry and confocal laser scanning fluorescence microscopy. 
HUVECs were cultured on collagen-treated µ-Slides (ibidi, Martinsried, Germany). The NPR-
A/B antagonist HS-142-1 (Morishita et al., 1991) was kindly provided by Dr. Y. Matsuda, Kyowa 
Hakko Kogyo Co., Ltd. (Shizuoka, Japan). cANP was from Bachem (Weil am Rhein, Germany). 
HUVECs and samples of the mouse cremaster muscle (immediately dissected after histamine 
treatment) were analyzed immunocyto/ histochemically and by confocal fluorescence 
microscopy as previously described (Fürst et al., 2005). The following antibodies and reagents 
were used: mouse monoclonal anti-VE-cadherin (Santa Cruz, Heidelberg, Germany), rabbit 
polyclonal anti-phospho-Tyr731-VE-cadherin (Biosource/Invitrogen, Karlsruhe, Germany), rabbit 
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polyclonal anti-phospho-MLC2 (Thr18/Ser19) (Cell Signaling/New England Biolabs, Frankfurt a. 
M., Germany), rhodamine phalloidin (Invitrogen, Karlsruhe, Germany), Alexa Fluor 633-linked 
goat anti-mouse (Invitrogen), and Alexa Fluor 488-linked goat anti-rabbit (Invitrogen).  
Western blot analysis. HUVEC were cultured in collagen-treated 6-well plates or 60 mm-
dishes. Western blot analysis was performed as previously described (Kiemer et al., 2002a). 
The following antibodies were used: rabbit polyclonal anti-phospho-Tyr731-VE-cadherin 
(Biosource), mouse monoclonal anti-VE-cadherin (Santa Cruz), rabbit polyclonal anit-phospho-
MLC2 (Thr18/Ser19) (Cell Signaling), and MLC2 (Santa Cruz). 
 
Statistical analysis. Statistical analysis was performed with the GraphPad Prism software 
version 3.03 (GraphPad Software, San Diego, CA). Unpaired t test was used to compare two 
groups. To compare three or more groups, one-way ANOVA followed by Newman-Keuls post 
hoc test was used. 
 
 
Results 
 
ANP protects against an inflammation-impaired endothelial barrier function in vivo. To 
judge endothelial permeability in vivo, we measured the extravasation of FITC-dextran (150 
kDa) via intravital fluorescence microscopy in postcapillary venules of the mouse cremaster 
muscle. 20 min after i.a.-application of ANP (bolus sufficient to reach 200 nM plasma 
concentration), histamine (30 µM) was superfused for 10 min. Histamine evoked a strong leak 
of FITC-dextran from the blood into the adjacent tissue. ANP clearly abrogated the histamine-
induced extravasation (Figure 1A, upper panel). Movies of this extravasation are presented as 
supplemental data (movie1: control; movie2: histamine; movie3: ANP+histamine). ANP alone 
(at least in the observed 20 min pre-treatment) seems to slightly increase basal permeability 
(please note the different ordinate scales in Figure 1A), but this effect is statistically not 
significant (Figure 1A, lower left panel). Moreover, we aimed to appraise the therapeutical 
impact of ANP by comparing its beneficial effect to that of a strong anti-inflammatory drug. Thus, 
we treated mice with a high dose of dexamethasone (i.p., 10 mg/kg, 2 h) before applying 
histamine (30 µM). The glucocorticoid completely prevented the histamine-induced 
extravasation of FITC-dextran. 
As a second approach for detecting changes of endothelial permeability in vivo, we measured 
hematocrit levels. Rats were treated with histamine (i.v. bolus sufficient to reach 1 µM plasma 
concentration) and hematocrit was determined after 30 min. Due to a reduction of plasma 
volume, i.e. augmented fluid extravasation, histamine evoked a strong hematocrit increase. 
ANP (bolus injection sufficient to reach 200 nM plasma concentration, 15 min pre-treatment) 
significantly reduced the permeability-increasing effect of histamine (Figure 1B). 
 
Characterization of the barrier protecting effect of ANP in vitro. Data about an influence of 
ANP on histamine-induced endothelial leakage in vitro are completely lacking. Thus, we first 
aimed to verify the effect of ANP in human umbilical vein endothelial cells (HUVECs). To judge 
permeability changes, transendothelial electrical resistance (TEER) was measured. Upon 
applying histamine, the electrical resistance of a HUVEC monolayer rapidly drops within 
seconds and recovers after approx. 10 min. The extent of this effect depends on the histamine 
concentration used: the resistance is lowered to 55% by 10 µM and to 85% by 1 µM histamine 
(Figure 1C, left). ANP (1 µM, 30 min pre-treatment) attenuates the drop-down of electrical 
resistance evoked by histamine (Figure 1C, middle). The statistic analysis of all experiments (n 
= 4) performed is depicted in the right panel of Figure 1C. The large variability of the 
ANP+histamine group expresses the fact that in 2 of the 4 experiments ANP did not only 
attenuate the effect of histamine, but even increased the endothelial resistance, i.e. led to a less 
permeable endothelium, even if compared to the basal resistance under control conditions. In 
summary, ANP strongly alleviates endothelial barrier dysfunction induced by histamine in vitro. 
This warrants the usage of this system for the following investigations into the action of ANP on 
adherens junctions and the contractile machinery. 
 
ANP abolishes the histamine-evoked changes of adherens junction morphology and 
inhibits the histamine-induced VE-cadherin tyrosine phosphorylation. Histamine (1 µM) 
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leads to strong changes of AJ morphology: the VE-cadherin, β-catenin, and p120ctn seam, 
properly build in untreated endothelial cells (control), becomes fringy, indicating an AJ 
disassembly, i.e. the retraction of the inter-endothelial VE-cadherin homodimers and/or an intra-
membranous lateral shift (Figure 2 A-C). Endothelial cells treated with ANP alone did not show 
any effect on AJs. Most importantly, ANP (1 µM, 30 min pretreatment) clearly abolishes the 
detrimental effects induced by histamine (Figure 2, A-C). 
To clarify which natriuretic peptide receptor is involved in mediating the beneficial actions of 
ANP, we treated cells with the NPR-A/B antagonist HS-142-1 (10 µg/ml, 10 min before ANP) 
and found that the effects on VE-cadherin disassembly were prevented by this inhibitor. The 
NPR-C receptor agonist cANF (1 µM, 30 min before histamine) was not able to mimic the 
effects of ANP (Figure 2A). Compared to NPR-B, NPR-A binds ANP with a much higher affinity. 
Thus, our results suggest that the action of ANP is mainly transduced by NPR-A. The C-
receptor seems not to be involved. 
Phosphorylation of the VE-cadherin Tyr731 residue is associated with AJ disassembly and strong 
endothelial leakage in vitro (Potter et al., 2005). First, we verified that Tyr731 is also 
phosphorylated by histamine in vivo: Vessels of the mouse cremaster muscle show a strong 
increase of Tyr731 phosphorylation induced by histamine (30 µM, 10 min, Figure 3A) and the 
same pronounced localization at cell fringes (Figure 3A, longitudinal vessel section) as in the in 
vitro situation (Figure 3B). Most importantly, as shown both by microscopic (Figure 3B) and by 
Western blot analysis (Figure 3C), ANP completely blocked the histamine-induced VE-cadherin 
Tyr731 phosphorylation. ANP alone did not evoke any alterations of the phosphorylation (Figure 
2B). Our data clearly point towards a protecting effect of ANP on the integrity of endothelial 
adherens junctions. 
 
ANP reduces the histamine-evoked activation of myosin light chain (MLC) and the 
formation of F-actin stress fibers. The generation of contractile forces (interaction of actin and 
myosin) is governed by MLC Thr18/Ser19-phosphorylation. Histamine treatment time-
dependently leads to a strong phosphorylation of MLC, which was analyzed microscopically 
(Figure 4A) and by Western blotting (Figure 4B). Moreover, histamine evokes a strong change 
in F-actin organization. While quiescent endothelial cells show a cortical F-actin localization, 
histamine induces the formation of long, cell-spanning stress fibers (Figure 4C). ANP clearly 
reduces both MLC phosphorylation (Figure 4, A and B) and F-actin stress fiber formation 
(Figure 4C). ANP alone had no effect on these parameters (Figure 4, A-C). These results 
indicate that ANP prevents histamine-evoked activation of the endothelial cell contraction 
system. 
Furthermore, we investigated which NP receptor subtype was involved in mediating these 
effects. The NPR-A/B inhibitor HS-142-1 (10 µg/ml, 10 min before ANP) blocked the effects of 
ANP on MLC phosphorylation (Figure 4A) and stress fiber formation (Figure 4C). The NPR-C 
agonist cANF (1 µM, 30 min) was not able to show beneficial effects (Figure 4, A and C). Thus, 
NPR-A/B could be regarded as the major receptors for transducing the actions of ANP in our 
setting. 
 
 
Discussion 
 
Many severe pathologies like sepsis or atherosclerosis are associated with an inflammation-
impaired endothelial barrier function leading to an increased plasma extravasation, and thus 
edema formation (Volk and Kox, 2000; Poredos, 2001). Proinflammatory mediators, such as 
TNF-α or histamine, are involved in the pathogenesis of these disorders and are strong 
inducers of vascular leakage. Current therapies against an inflammation-evoked barrier 
dysfunction (e.g. the administration of glucocorticoids or antihistamines) are often insufficient or 
even fail (van Nieuw Amerongen and van Hinsbergh, 2002). Therefore, new therapeutical 
options are needed. Strong progress has been made in the recent years concerning the 
mechanisms involved in the regulation of endothelial permeability (Mehta and Malik, 2006). 
However, substances that counteract an inflammation-induced vascular leakage by specifically 
influencing these mechanisms are still largely lacking (van Nieuw Amerongen and van 
Hinsbergh, 2002). 
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Initially, the physiological action of the cardiovascular hormone ANP, i.e. the reduction of blood 
pressure, was mainly ascribed to its natriuretic, diuretic, and vasodilating action. However, ANP 
was also found to increase endothelial permeability (Huxley et al., 1987). Recently, this effect 
was proven to be crucial for the chronic control of plasma volume by ANP (Sabrane et al., 
2005). Beyond these permeability increasing effects on quiescent endothelial cells, ANP has 
increasingly been recognized to possess barrier protecting actions on an inflammation-activated 
endothelium: We could demonstrate that ANP attenuates the TNF-α-induced expression of 
adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) by inhibiting NF-κB 
activation and p38 mitogen-activated protein kinase (MAPK) signaling (Weber et al., 2003; 
Kiemer et al., 2002b). In this context, we showed that ANP protects against TNF-α-evoked 
endothelial barrier dysfunction in HUVECs (Kiemer et al., 2002a). ANP was also shown to lower 
endothelial leakage in vitro induced by the pro-inflammatory stimuli thrombin (Baron et al., 
1989) and VEGF (Pedram et al., 2002). 
Thus, ANP has commonly been suggested to work as a barrier protecting agent. Surprisingly, 
an obvious question has as yet not been answered precisely: Can ANP be used as 
pharmacological agent to prevent endothelial barrier dysfunction in vivo? This issue is of special 
interest, since the drug ANP (carperitide, HANP®) could open new therapeutical options for 
protecting endothelial barrier function. In the present study, we for the first time show that ANP 
administered at a pharmacological concentration is able to prevent endothelial leakage in a 
(histamine-induced) inflammatory setting in vivo. Different aspects of endothelial permeability 
were used as read-out parameters and were all beneficially influenced by ANP: macromolecular 
permeability (FITC-dextran extravasation), plasma volume/fluid changes (hematocrit), and 
electrical resistance (TEER measurement). Compared to the maximal increase of FITC-dextran 
extravasation induced by histamine (time point 45 min in Figure 1A), ANP led to approx. 65% 
reduction. Due to this pronounced effect, a therapeutical impact of ANP is not unlikely. A 
complete blockage of the deleterious effect of histamine was observed in the presence of a 
extraordinary high dosage of the glucocorticoid dexamethasone, a highly potent anti-
inflammatory drug. 
Former studies dealing with ANP and vascular permeability served as valuable hints toward an 
in vivo relevance of ANP as barrier protecting agent. However, these reports did not concisely 
test the hypothesis that administered ANP exerts beneficial effects on endothelial barrier 
dysfunction in vivo, because they (i) either used ex vivo models or (ii) focused on the 
endogenous ANP system: (i) Three older reports demonstrate that pharmacological 
concentrations of ANP attenuate changes of pulmonary wet weight induced by toxic agents like 
reactive oxygen metabolites, paraquat, or arachidonic acid in ex vivo models of isolated-
perfused lungs from rabbits or guinea pigs (Lofton et al., 1991; Inomata et al., 1987; Imamura et 
al., 1988). (ii) Blockade of endogenous ANP was shown to deteriorate pulmonary edema 
formation in rats suffering from high altitude-induced (Irwin et al., 2001) or HCl-evoked 
(Wakabayashi et al., 1990) pulmonary vascular leakage, whereas mice lacking the major ANP-
degrading enzyme neutral endopeptidase were found to be less susceptible for pulmonary 
leakage (Irwin et al., 2005a). Interestingly, Pedram et al. showed that VEGF-induced vascular 
leakage is attenuated in ANP-overexpressing mice, whereas these mice are not protected 
against histamine-evoked leakage (Pedram et al., 2002). This might be due to the much lower 
ANP levels in these animals (plasma level: ~40 pM) compared to our setting, in which ANP is 
exogenously supplied to reach a pharmacological plasma concentration of 200 nM. Recently, 
our group could demonstrate that ANP-treated mice (plasma level: ~35 nM) are protected 
against LPS-induced septic shock (Ladetzki-Baehs et al., 2007). Since endothelial 
hyperpermeability is an important pathological feature of sepsis, it can be speculated that the 
barrier protecting effect of ANP contributes to the beneficial action in the mouse septic shock 
model. Our results suggest that pharmacological concentrations of ANP show additional, highly 
valuable effects beyond its action as an endogenous regulator of permeability. 
Adherens junctions and the contractile apparatus are key players in the regulation of endothelial 
permeability. Both the loss of VE-cadherin function and the activation of MLC result in 
decreased transendothelial electrical resistance (Garcia et al., 1997; van Buul et al., 2005) and 
increased macromolecular permeability (Nwariaku et al., 2002; Garcia et al., 1995). Studies 
investigating the action of ANP on these key systems are as yet completely lacking. We provide 
for the first time evidence that ANP interacts with these systems, since we showed that ANP 
attenuates both adherens junction disassembly (morphological changes and Tyr731 
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phosphorylation of VE-cadherin) and activation of the contractile apparatus (phosphorylation of 
MLC and rearrangement of F-actin) induced by histamine. Furthermore, we could demonstrate 
that ANP exerts these effects predominantly via the natriuretic peptide receptor (NPR)-A. Since 
this receptors represent particulate guanylate cyclases, it can be speculated that the actions of 
ANP might be mediated via the second messenger cyclic guanosine monophosphate (cGMP). 
Our results add further support to the hypothesis that ANP is an endothelium protecting agent, 
since it directly counteracts the detrimental effects of proinflammatory mediators on endothelial 
barrier function.  
Only few data exist about the action of ANP on subcellular systems contributing to permeability 
regulation. We and others could demonstrate that ANP inhibits F-actin stress fiber formation 
induced by TNF-α (Kiemer et al., 2002a; Irwin et al., 2005b) or VEGF (Pedram et al., 2002). 
Interestingly, one study reports that ANP influences tight junctions in bovine aortic endothelial 
cells (Pedram et al., 2002). In contrast to the dense aortic endothelium, the occurrence of tight 
junctions is limited in the venous endothelium (Ogunrinade et al., 2002), which represents the 
predominant site of endothelial hyperpermeability and was investigated in the present study. 
In summary, we have revealed ANP as a potent endothelial barrier protecting agent in vivo. 
Moreover, we have identified adherens junctions and the contractile apparatus as important 
subcellular systems targeted by ANP. Most importantly, our study highlights ANP as an 
interesting pharmacological compound opening a new therapeutic option for the prevention of 
vascular leakage. This warrants further efforts aiming for an expansion of the therapeutic 
indications of natriuretic peptides. 
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Figure 1. ANP attenuates histamine-induced increase of endothelial permeability in vivo and in vitro. A, Extravasation of 
FITC-dextran (150 kDa) from venules of the mouse cremaster muscle was measured. Upper left panel: Mice were pre-
treated with Ringer solution (control and histamine group), or with ANP (i.a. bolus injection sufficient to reach 200 nM 
plasma concentration). After 20 min, histamine (30 µM) was superfused for 10 min (histamine and ANP+histamine 
group). Data are expressed as mean ± SEM (n = 6). *p≤0.05 vs. histamine. Upper right panel: One representative image 
is shown for each group of treatment (at time point 45 min for control, histamine, and histamine+ANP; at time point 30 
min for ANP alone). Videos showing this FITC-dextran extravasation (movie1: control; movie2: histamine; movie3: 
ANP+histamine) are available as supplemental data. Lower left panel: Mice were treated with Ringer solution (control 
group) or with ANP (i.a. bolus injection sufficient to reach 200 nM plasma concentration). Data are expressed as mean ± 
SEM (n = 6). Lower right panel: Mice were pre-treated with Ringer solution (histamine group) or with dexamethasone 
(i.p., 10 mg/kg bodyweight) for 2 h. Histamine (30 µM) was superfused for 10 min. Data are expressed as mean ± SEM 
(n = 2). B, Plasma volume changes were determined by measuring hematocrit values. Rats were pre-treated with PBS 
(control) or with ANP (i.v., bolus injection sufficient to reach 200 nM plasma concentration). After 15 min, histamine was 
applied (i.v., bolus injection sufficient to reach 1 µM plasma concentration). 30 min later, blood samples were taken and 
hematocrit was measured. Data are expressed as mean ± SEM (n = 3). *p≤0.05 vs. histamine. 
C, Transendothelial electrical resistance (TEER) was used to judge changes in endothelial permeability of HUVECs. 
Left panel: Histamine concentration-dependently decreases TEER values. Middle panel: ANP (1 µM, 30 min pre-
treatment) attenuates the histamine-induced decrease of electrical resistance. One representative graph out of 4 
independent experiments is shown, each. Right panel: Statistical analysis of all experiments performed (n = 4). Data are 
expressed as mean ± SEM. *p≤0.05 vs. histamine. 
 
Figure 1
A
50
60
70
80
90
100
110
-10 -5 0 5 10 15
no
rm
al
iz
ed
 T
EE
R
 [%
]
time [min]
histamine [10 µM]
histamine [1 µM]
histamine
80
85
90
95
100
105
-10 -5 0 5 10 15
time [min]
no
rm
al
iz
ed
 T
EE
R
 [%
]
histamine
ANP +
histamine
histamine
-20
-15
-10
-5
0
5
10
15
20
control histamine ANP +
histamine
no
rm
al
iz
ed
 T
EE
R
 [%
]
*
B
0
100
200
300
400
500
600
0 10 20 30 40 50 60
time (min)
histamine
ANP + histamine
control
ANP
* * *
hi ine
A  istamine
c tr l
ex
tr
av
as
at
io
n
of
 F
IT
C
-d
ex
tr
an
(m
ea
n 
gr
ay
 v
al
ue
s)
ANP
control
0 5 10 15 20 25 30
ANP
time (min)
0
10
20
30
40
50
60
ex
tr
av
as
at
io
n
of
 F
IT
C
-d
ex
tr
an
(m
ea
n 
gr
ay
 v
al
ue
s)
ANPANP + histamine
100 µm10  µm
histaminecontrol
C
histamine
histamine dexamethasone +histamine
0
100
200
300
400
500
600
ex
tr
av
as
at
io
n
of
 F
IT
C
-d
ex
tr
an
(m
ea
n 
gr
ay
 v
al
ue
s)
0 5 10 15 20 25 30
time (min)
histamine
56
58
60
62
64
control histamine ANP +
histamine
he
m
at
oc
rit
[%
]
*
no
rm
al
iz
ed
 T
EE
R
 [%
]
no
rm
al
iz
ed
 T
EE
R
 [%
]
no
rm
al
iz
ed
 T
EE
R
 [%
]
ex
tr
av
as
at
io
n
of
 F
IT
C
-d
ex
tr
an
(m
ea
n 
gr
ay
 v
al
ue
s)
ex
tr
av
as
at
io
n
of
 F
IT
C
-d
ex
tr
an
(m
ea
n 
gr
ay
 v
al
ue
s)
ex
tr
av
as
at
io
n
of
 F
IT
C
-d
ex
tr
an
(m
ea
n 
gr
ay
 v
al
ue
s)
ex
tr
av
as
at
io
n
of
 F
IT
C
-d
ex
tr
an
(m
ea
n 
gr
ay
 v
al
ue
s)
ex
tr
av
as
at
io
n
of
 F
IT
C
-d
ex
tr
an
(m
ea
n 
gr
ay
 v
al
ue
s)
he
m
at
oc
rit
[%
]
he
m
at
oc
rit
[%
]
6  ANP 96 
  
 
 
 
 
 
 
 
Figure 2. ANP inhibits the histamine-evoked morphological changes of adherens junctions. HUVECs were left untreated 
(control) or were treated with histamine (1 µM, 2 min) alone or in combination with ANP (1 µM, 30 min pre-treatment) or 
the NPR-C agonist cANF (1 µM, 30 min pre-treatment). The NPR-A/B receptor antagonist HS142-1 (10 µg/ml) was 
given 10 min before ANP. Immunocytochemistry and confocal fluorescence microscopy were performed to analyze 
morphological changes of (A) VE-cadherin, (B) β-catenin, and (C) p120ctn. One representative image out of three 
independent experiments is shown, each. 
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Figure 3. ANP blocks histamine-induced VE-cadherin Tyr731-phosphorylation. A, Histamine induces phosphorylation of 
VE-cadherin at Tyr731 in vivo. Mice were treated as described in Figure 1A. Samples of the mouse cremaster muscle 
were analyzed via immunohistochemistry and confocal fluorescence microscopy. Histamine (30 µM) was superfused for 
the indicated times. One representative image out of 3 independent experiments is shown. B-C, ANP inhibits histamine-
induced VE-cadherin Tyr731-phosphorylation in vitro. HUVECs were left untreated (control), were treated with histamine 
(1 µM, 5 min) or ANP (1 µM, 30 min) alone, or with ANP (1 µM) 30 min before histamine was applied. The VE-cadherin 
Tyr731-phosphorylation was analyzed via immunocytochemistry and confocal fluorescence microscopy (B, n = 3) or 
biochemically via Western blot (C, n = 2). 
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Figure 4. ANP inhibits histamine-induced MLC2 Thr18/Ser19-phosphorylation and stress fiber formation. A-C, HUVECs 
were left untreated (control) or were treated with histamine (1 µM, 5 min) alone or in combination with ANP (1 µM, 30 
min pre-treatment) or the NPR-C agonist cANF (1 µM, 30 min pre-treatment). The NPR-A/B receptor antagonist HS142-
1 (10 µg/ml) was given 10 min before ANP. MLC2 Thr18/Ser19-phosphorylation and F-actin were analyzed via 
immunocytochemistry and confocal fluorescence microscopy (A, C). MLC2 Thr18/Ser19-phosphorylation was additionally 
analyzed via Western blot (B). One representative image out of at least three independent experiments is shown, each. 
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